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Abstract
LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY FOR THE STUDY OF ARACHIDONIC ACID
METABOLITES
Xiaojing Liu
Ian A. Blair, PhD
Arachidonic acid (AA) oxidation metabolism has been an important research topic for decades, and
numerous oxidation products as well as enzymes involved in AA metabolism together with their
downstream metabolites have been identified, although unknown pathways still remain to be
characterized. In the present a study a new AA metabolite, 11-oxo-eicosatetraenoic acid (ETE), generated
from a major product of cyclooxygenase (COX-2), 11(R)-hydroxyeicosatetraenoic acid (HETE), through
15-hydroxyprostaglandine dehydrogenase (15-PGDH)-mediated oxidation. 11-Oxo-ETE was found to have
an anti-proliferative effect on human umbilical vein endothelial cells (HUVECs), with a similar IC50 to a
well- known anti-inflammatory mediator, 15-deoxy-12,14-prostaglandin J2 (15d-PGJ2). It was also found
that 11-oxo-ETE could be inactivated through the glutathione-S-transferase (GST)/glutathione (GSH)
pathway by forming a GSH adduct, or by undergoing reduction to 11(S)-HETE through metabolism by
unknown reductases.
AA is also subject to non-enzymatic oxidation due to its bis-allylic hydrogen atoms and four double
bonds. Chiral LC-MS methods were used to distinguish the enzymatic and non-enzymatic products by
monitoring the relevant products that were formed. Non-enzymatic pathways generate racemic mixtures,
while enzymatic pathways are normally highly stereoselective. It is known that both enzymatic and nonenzymatic oxidation of AA followed by decomposition of the resulting oxidized intermediates, can
generates short-chain aldehydes such as 4-hydroperoxy-2(E)-nonenal (HPNE), 4-hydroxy-2(E) nonenal
(HNE), and 4-oxo-2(E)-nonenal (ONE). However, it was discovered that the endoperoxide product of COX-2,
PGG2, is a major contributor to the formation of these aldehydes. Moreover, PGG2 and other
hydroperoxides generate HPNE or HNE with different chiral characteristics. From COX-2 expressing
human colorectal adenocarcinoma epithelial cell line (LoVo) cell lysate, 4(S)-HNE was detected with high
enantiomeric purity indicating that the primary source was prostaglandin G2 (PGG2) and not 15hydroperoxyeicosatetraenoic acid (HPETE) as had been previously suggested.
Finally, through studies of 11(R)-HPETE and 15-HPETE decomposition, a new carboxylate-containing
aldehyde, 11-oxoundeca-5,8-dienoic acid (OUDE) was identified. OUDE contains the -terminus of the lipid
hydroperoxide precursor and is analogous to HNE, which is derived from the -terminus. Nuclear
magnetic resonance spectroscopy (NMR) together with chiral liquid chromatography-mass spectrometry
(LC-MS) analysis showed that OUDE was a mixture of two double bond isomers. It has been proposed
that the two isomers are generated as a result of a rearrangement reaction subsequent to the formation
of OUDE. In addition, , by monitoring the chirality of the HNE that was formed from 11(R)-HPETE and
15-HPETE decomposition, a homolytic mechanism for HNE formation has been proposed.
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Abstract

LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY FOR THE STUDY
OF ARACHIDONIC ACID METABOLITES

Xiaojing Liu
Ian A. Blair, PhD

Arachidonic acid (AA) oxidation metabolism has been an important research
topic for decades, and numerous oxidation products as well as enzymes
involved in AA metabolism together with their downstream metabolites have
been identified, although unknown pathways still remain to be characterized.
In the present a study a new AA metabolite, 11-oxo-eicosatetraenoic acid
(ETE), generated from a major product of cyclooxygenase (COX-2), 11(R)hydroxyeicosatetraenoic acid (HETE), through 15-hydroxyprostaglandine
dehydrogenase (15-PGDH)-mediated oxidation. 11-Oxo-ETE was found to
have an anti-proliferative effect on human umbilical vein endothelial cells
(HUVECs), with a similar IC50 to a well- known anti-inflammatory mediator,
15-deoxy-12,14-prostaglandin J2 (15d-PGJ2). It was also found that 11-oxoETE

could

be

inactivated

through

the

glutathione-S-transferase

(GST)/glutathione (GSH) pathway by forming a GSH adduct, or by
undergoing reduction to 11(S)-HETE through metabolism by unknown
reductases.

iv

AA is also subject to non-enzymatic oxidation due to its bis-allylic hydrogen
atoms and four double bonds. Chiral LC-MS methods were used to distinguish
the enzymatic and non-enzymatic products by monitoring the relevant
products that were formed. Non-enzymatic pathways generate racemic
mixtures, while enzymatic pathways are normally highly stereoselective. It
is known that both enzymatic and non-enzymatic oxidation of AA followed by
decomposition of the resulting oxidized intermediates, can generates shortchain aldehydes such as 4-hydroperoxy-2(E)-nonenal (HPNE), 4-hydroxy-2(E)
nonenal (HNE), and 4-oxo-2(E)-nonenal (ONE). However, it was discovered
that the endoperoxide product of COX-2, PGG2, is a major contributor to the
formation of these aldehydes. Moreover, PGG2 and other hydroperoxides
generate HPNE or HNE with different chiral characteristics. From COX-2
expressing human colorectal adenocarcinoma epithelial cell line (LoVo) cell
lysate, 4(S)-HNE was detected with high enantiomeric purity indicating that
the

primary

source

was

prostaglandin

G2

(PGG2)

and

not

15-

hydroperoxyeicosatetraenoic acid (HPETE) as had been previously suggested.
Finally, through studies of 11(R)-HPETE and 15-HPETE decomposition, a new
carboxylate-containing aldehyde, 11-oxoundeca-5,8-dienoic acid (OUDE) was
identified. OUDE contains the –terminus of the lipid hydroperoxide precursor
and is analogous to HNE, which is derived from the –terminus.
magnetic

resonance

spectroscopy

(NMR)

together

with

chiral

Nuclear
liquid

chromatography-mass spectrometry (LC-MS) analysis showed that OUDE
was a mixture of two double bond isomers. It has been proposed that the
two isomers are generated as a result of a rearrangement reaction
v

subsequent to the formation of OUDE. In addition, , by monitoring the
chirality of the HNE that was formed from 11(R)-HPETE and 15-HPETE
decomposition, a homolytic mechanism for HNE formation has been proposed.
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Chapter 1 General Introduction
1.1 Lipid classification
1.1.1 Lipid classification by function
Lipids can be classified by their functions into storage lipids, structural lipids
(membrane lipids), hormones, and vitamins. Storage lipids exist in the form
of triacylglycerols, while structural lipids usually contain a polar head and a
long carbon chain tail. Based on the polar head and carbon chain
compositions, membrane lipids can be further classified into different
categories. Hormones and vitamins represent only a small component of
cellular lipids when compared with storage and structural lipids, but they play
important roles in regulating biological process. Fatty acids which are major
components of lipids, can be classified as saturated and unsaturated based
on the presence or absence of double bonds. Polyunsaturated fatty acids
(PUFAs) are subject to oxidation by chemical oxidants or enzymes and the
resulting oxidation products can function as “hormone-like” signaling
molecules.
1.1.2 Phospholipids
Phospholipids are major components of all cell membranes where they form
lipid bilayers. Most phospholipids contain a diglyceride, a phosphate group,
and a polar head group such as choline. However, sphingolipids, which
represent a major class of phospholipid, contain a sphingosine moiety instead
of glycerol. The structure of a typical glycerophospholipid, sn1-stearoyl-2arachidonoyl-phosphatidylinositol is shown in Figure 1.1. Glycerol forms an
1

ester bond with the carboxylic acid group of stearic acid at the sn-1 position,
and the other ester bond at the sn-2 position is formed with arachidonic acid.
At-the sn-3 position, there is a polar phosphoinositol head group. As
illustrated in Figure 1.1, the arachidonyl substituent has 4 double bonds,
while the stearoyl substituent is fully saturated. In addition to arachidonic
acid, there are numerous other unsaturated and polyunsaturated fatty acids.
These fatty acids are classified as -9, -6 or -3, depending on the position
of the last double bond. For example, arachidonic acid (AA) has a double
bond at C14-C15, and the terminal carbon is at C-20, which is designated as
-1. Therefore, the first double bond is at -6.

2

Figure 1.1. Structures of unsaturated fatty acids and sn-1-stearoyl-2arachidonoyl phosphatidylinositol.

AA has 20 carbon atoms and 4 double bonds, so it can also be abbreviated as
20:4-6 or 20:4n-6. Similarly, docosahexaenoic acid (common name: DHA)
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has 22 carbons and 6 double bonds, and the last double bond is at C19-C20,
so it’s abbreviated as 22:6-3 or 22:6n-3.
Unsaturated fatty acids with more than three double bonds are frequently
seen in animals, while in plants there are usually less than three. The transdouble bonds allow them to be less tightly packed than saturated fatty acids,
so membranes containing unsaturated fatty acids have some degree of
fluidity. Moreover, compared to saturated fatty acids, the unsaturated fatty
acids are much more readily oxidized, and the corresponding oxidation
products are important biological signal mediators. When there is more than
one double bond, there is usually a methylene group connecting the two
double bonds, which is also known as a bis-allylic configuration. The
abstraction of a bis-allylic hydrogen atom is an important step in lipid
peroxidation and in enzymatic oxidation.

1.2

Arachidonic acid metabolism

1.2.1 The importance of arachidonic acid
There have been numerous studies on AA metabolism because it is the
precursor of a diverse biologically active family of biologically active lipid
mediators known as eicosanoids (1). They have multiple functions in
inflammation, cancer or immunity through modulating signaling pathways,
transcription factor activity and gene expression. The eicosanoids derived
from arachidonic acid are called -6 eicosanoids and are often proinflammatory either as G-protein coupled receptor (GPCR) agonists or as
nuclear transcription factor ligands (2,3,4,5).
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1.2.2 Overview of AA metabolism

Figure 1.2: Simplified scheme of AA metabolism. R1: stearoyl (18:0);
DAG: Diacylglycerol; DAGL: DAG lipase; PI: Phosphatidylinositol; PLA2:
phospholipase A2; PLC: Phospholipase C; AEA: Arachidonoylethanolamide
(anandamide); FAAH: Fatty acid amide hydrolase; AA: arachidonic acid

AA in mammals mainly exists as an esterified form in acylglycerides, and
phospholipids.

Generally,

before

esterified

AA

can

be

converted

to

eicosanoids, it has to be released as a free fatty acid. For example, as shown
in

Figure

1.2,

esterified

arachidonic

acid

at

the

sn-2

position

on

phosphatidylinosotol can be directly released by the phospholipase A2 (PLA2)
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enzyme (6). Alternatively, Phospholipase C (PLC)-mediated hydrolysis of
phospholipids can first occur at the sn-3 position, in which case the polar
phosphoinositol head group is removed, forming a diacylglycerol (DAG). Then
DAG is further metabolized by DAG lipase (DAGL) to release free arachidonic
acid. There are also additional sources of free arachidonic acid (7,8). For
example, arachidonylethanolamide (anandamide, AEA) is an endogenous
cannabinoid neurotransmitter. It is the substrate for enzyme fatty acid amide
hydrolase (FAAH), which converts AEA into ethanolamine and arachidonic
acid. In most of the tissues, the PLA2 and PLC pathways play the major role,
while recent research has shown that in brain, the FAAH pathway are more
important than the other two (8).
Besides enzymatic pathways, AA is also subject to autoxidation both in vitro
and in vivo. Since arachidonic acid has four double bonds, and three bisallylic hydrogen atoms, when it is exposed to air or free radicals, or when it is
heated, it is readily oxidized (9). Although the intracellular environment is
mostly reducing, within mitochondria there is a pool of free radicals, which
could attack AA, and initiate autoxidation. Autoxidation products are different
from

enzymatic

products

in

that

they

are

racemic

rather

than

enantiomerically pure metabolites observed from enzymatic reactions. Thus,
although hydroperoxyeicosatetraenoic acids (HPETEs) can be generated both
from enzymatic and non-enzymatic arachidonic acid oxidation, a chiral
analysis can distinguish the two pathways. Furthermore, autoxidation occurs
with little regioselectivity, which leads to a myriad of products. Thus, the
initially formed HPETEs undergo further oxidation to generate a family of
6

eicosanoids known as isoprostanes (10). Several of the isoprostanes have
been widely used as biomarkers of oxidative stress (11,12). AA-derived -6
eicosanoids are mostly pro-inflammatory, while -3-derived eicosanoids are
much less inflammatory. It has been proposed that -3 eicosapentaenoic
acid has some health benefits because it can compete with AA as the
substrate of related enzymes to lower the formation of inflammatory
eicosanoids (13,14).

1.3

COX-2 pathway

1.3.1 COX structure and catalytic mechanism

Figure 1.3 Crystal structures of ovine COX-1 (left) and murine COX-2
(right) homodimers by Browner and Kurumbail. The red color
represents the catalytic cofactor, heme, the blue area is the dimerization
domain, and the yellow color is membrane binding domain. The peroxidase
active site is on the top cleft of each monomer. This figure is modified from
(15).

Cyclooxygenase (COX) is a membrane protein located on the inner and outer
membrane of nuclear envelope, and the surface of the endoplasmic reticulum
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lumen. It has dual catalytic functions. There are both cyclooxygenase and
peroxidase (POX) active sites in one enzyme. The cyclooxygenase site
converts AA into PGG2 and HPETEs, while the peroxidase site reduces the
hydroperoxide groups in PGG2 or HPETEs to the corresponding hydroxyl
groups. As shown in Figure 1.3, the red color represents the cofactor heme,
while the open cleft on top of each monomer is the POX site. The COX and
POX activities are functionally interdependent. As shown in Figure 1.4, it has
been generally accepted that there is a protein radical formed during the
catalytic process. Alkyl hydroperoxides bind to heme in the POX site, and are
reduced to the corresponding alkyl hydroxyl, and meanwhile the resting
heme is oxidized to the oxyferryl form and a protoporphyrin radical cation
(Fe4+=O.) is formed. This intermediate is so unstable that it attacks the
neighboring tyrosine residue (385Tyr), and abstracts hydrogen from the
side chain, resulting in the formation of
The

385

385

385

Tyr

Tyr radical and oxyferryl Fe4+=O.

Tyr radical then abstracts pro-S hydrogen at C13 of arachidonic acid,

which binds to COX active site. Then

385

Tyr is recycled, while the radical is

transferred to AA. The C11-C12 double bond then relocates to C12-C13 and
forms a conjugate double bond with C14-C15, the C13 radical is also
transferred to C11. Then oxygen is inserted at the C11 position and the
radical is transferred to oxygen, which rapidly attacks C8-C9 double bond,
and form a dioxygen (endoperoxide) bridge between C11 and C9, together
with a C8 radical. This is then followed by a C8 radical attraction of C12-C13
double bond and formation of C8-C12 single bond, together with a C13
radical. After translocation of C13 radical and C14-C15 double bond, C15 is
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formed and followed by oxygen attachment. Finally this PGG2 precursor
abstracts a hydrogen atom from neighboring reducing environment and
forms the final PGG2. PGG2 will function as alkyl hydroperoxide and enter the
peroxidase site, where it is reduced to PGH2. Usually after several cycles, the
COX will lose it is activity, which is called COX suicide. The exact mechanism
is not clear yet, but there are reports showing it may be related with the
quench of tyrosine radicals or damage to COX protein by free radicals, and
the addition of phenol slows the inactivation process (16,17).
1.3.2 COX isoenzymes and diseases
Before 1991, only one COX was identified, and then after that, an inducible
COX isoenzyme was described by three independent groups (18,19,20).
Simmons and Herschman (19, 20) together with their colleagues found
mRNAs whose expression was induced in chicken and mouse fibroblasts in
response to src and tumor-promoting phorbol esters. Later, they found these
mRNAs encoded proteins shared 60% amino acid sequence with the earlier
COX mRNA, but their expression and their biological activity were quite
different. Thus, it is concluded that COX has two isoenzymes, COX-1 and
COX-2. COX-1 is constitutively expressed in many cells, while COX-2 is
induced in response to cytokines, hormones, growth factors, bacteria
endotoxin, and certain other stimuli. Thus, COX-2 is usually over-expressed
in inflammatory tissues or tumors. COX-1 functions as a house-keeping
enzyme and its products help to maintain normal biological processes.
However, COX-2 is related with many diseases, including inflammatory
disorders, cancer, diabetes, and so on. Over-expression of COX-2 contributes
9

to accumulation of prostaglandins, which are usually pro-inflammatory, as
described previously, although it was also reported that certain COX-2
mediated -3 fatty acids metabolites are anti-inflammatory (21).
1.3.3 COX inhibitors
COX is a target for developing anti-inflammatory drugs, known as nonsteroidal anti-inflammatory drugs (NSAIDs). Within the NSAIDs, aspirin was
the earliest developed. It also differs from other NSAIDs, in that it converts
COX-2 into a 15(R)-lipoxygenase (LOX), instead of completely inhibiting
COX-2 activity. It is also the only NSAID which covalently modifies COX-1
and COX-2, while other NSAIDs are usually competitive substrates of COX.
Aspirin completely inhibits both COX-1 activity, and switches COX-2 to a
15(R)-LOX, so PG synthesis is inhibited, and it has many side effects, such as
a pro-aggregatory effect due to inhibition of platelet COX-1-mediated
thromboxane A2 biosynthesis. Aspirin also causes irritation of the gastric
mucosa due to inhibition of PG synthesis. In order to overcome this effect,
COX-2 specific inhibitors have been developed, although they have significant
adverse cardiovascular effects (22).
It is known that among the NSAIDs, aspirin is the most effective anti-platelet
drug, because it can covalently modify COX-1, and more efficiently inhibit the
biosynthesis of pro-aggregatory thromboxane A2 (23). Moreover, there are
studies showing that daily doses of aspirin might help to reduce cancer risk
(24,25) .
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The mechanism through which aspirin functions as a chemoprevention agent
is still not quite clear yet, and no evidence shows whether a COX is involved
or not. Thus, more studies are needed to address these issues and to
develop safer chemoprevention candidates.
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Figure 1.4. The mechanism of cyclooxygenase and peroxidase
activity of COX. This figure is modified from (15).

1.4

15-PGDH pathway

1.4.1 15-PGDH structure and function
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Figure 1.5: Crystal structure of 15-PGDH. Figure 1.5a. the crystal
structure of 15-PGDH with NAD+ and PGE2 complex. Figure 1.5b. the
catalytic sites. Bottom, the chemical structures of PGE2 and dehydrated
product 15-keto-PGE2. Figure 1.5a and 1.5b are modified from ref (26)

The eicosanoids generated from COXs are not metabolically stable. Thus, the
overall eicosanoid levels are controlled both by COXs and by eicosanoid
catabolism enzymes.
hydroxyprostaglandin

Among the eicosanoid catabolism enzymes, 15dehydrogenase

(15-PGDH)

has

been

studied

intensively. 15-PGDH is an enzyme which converts the (S)-hydroxyl group at
carbon 15 on eicosanoids to a keto group. For example, PGE2 undergoes 15PGDH-mediated conversion to the biologically inactive 15-keto-PGE2 (Figure
1.5, which can be further metabolized to 13,14-dihydro-15-keto-PGE2 by a
specific reductase. 15-PGDH primarily uses NAD+ as its cofactor. Although
there is a type II 15-PGDH which uses NADP+ as its cofactor, type II 15PGDH has a Km value toward PGE2 which is two orders of magnitude higher
than NAD+ dependent 15-PGDH (27). In addition to being reduced, 15-keto13

PGE2 can undergo glutathione S-transferase (GST)-mediated conjugation
with glutathione (GSH). Other eicosanoids containing a 15(S)-hydroxyl group
can undergo a similar route of catabolism. The GSH conjugates have higher
polarity than their precursors, and they can be excreted out of cells through
relevant transporters.
1.4.2 15-PGDH substrates
Although 15-PGDH was first identified as an enzyme which degraded PGs,
subsequent studies revealed that LOX-type products, such as 15(S)-HETE,
12-HHT, and 12-HETE were also the substrates of 15-PGDH isolated from
human IL-60 leukemia cells (28). However, based on the data obtained
(Table 1.1), it was concluded that substrates containing -6 hydroxyl group
were more readily degraded by 15-PGDH. This suggests that 15-PGDH could
play an important role in the metabolism of many different eicosanoids.
1.4.3 15-PGDH and diseases
It has been reported that in many tumors and cancer cell lines, 15-PGDH is
down-regulated so that pro-proliferative PGs can accumulate (29). Eruslanov
et al. showed that delivery of 15-PGDH genes to mouse tumors greatly
reduces tumor development through increasing 15-PGDH expression and
removing accumulated PGE2 (30). Moreover, decreased PGE2 levels not only
decreased

tumor

growth

rate,

but

also

inhibited

the

release

of

immunosuppressive cytokines from CD11b cells associated with tumor cells.
Thus, besides COX-2, 15-PGDH is also a chemotherapy target. Another group
showed that COX-2 inhibitor therapy fails in some patients who are 15-PGDH
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deficient, suggesting that a combination of COX-2 inhibitors and 15-PGDH
stimulators provide a better chemoprevention approach (31).

Table 1.1. Substrate specificity of 15-prostaglandin dehydrogenase
obtained from HL-60 cells. hydroxyl-heptadecatrienoic acid (HHT);
hydroxyl-octadecadienoic acid (HODD); hydroxyl-eicosatetraenoic acid
(HETE). Activity with PGE2 was 5.4 nmol/min/mg protein. (Modified from
Table 1.1 in Metabolism of cyclooxygenase and LOX products by 15-PGDH
from human HL-60 leukemia cells (28)

1.5

Lipid

hydroperoxide

Non-enzymatic

decomposition

pathway
1.5.1 Hock rearrangement
For many years, it has been known that unsaturated lipids can generate
aldehydes, and compared to the lipid precursor, these aldehydes are much
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more reactive to cellular macromolecules and thiols. It was reported that
these aldehydes can modify proteins, DNA, and induce oxidative stress by
conjugating

to

GSH.

Among

these

aldehydes,

the

formation

of

malondialdehyde (MDA), 4-hydroxy-2(E)-nonenal (HNE), and 4-oxo-2(E)nonenal (ONE) are the most widely studied (32). However, the mechanism
by which the aldehydes are formed is still controversial. The Figures 1.6
to1.10 show some of the mechanisms proposed by different research groups.

Figure 1.6: Hock rearrangement, modified from the book
Comprehensive Organic Name Reactions and Reagents, by Zerong
Wang, (34)

The Hock rearrangement (or Hock cleavage) was first studied by Hock and
Schrader in 1936 (33). This reaction is initiated by protic or Lewis acid, which
promotes the rearrangement of hydroperoxides which have unsaturated
group (aryl or vinyl) attached to the carbon bearing the hydroperoxide group,
followed by the formation a oxycarbonium ion, which is further attacked by
water, initiating another rearrangement. This whole process can convert long
chain unsaturated fatty acid into shorter chain carbonyl compounds. This
16

mechanism

is

still

often

used

to

explain

the

conversion

of

lipid

hydroperoxides to reactive aldehydes.
1.5.2 Beta scission

Figure 1.7. Decomposition mechanism via formation of allylic radicals

This mechanism was originally proposed by the Marnett group (35). The
hydroperoxide group is reduced by iron, forming alkoxyl radical, which either
attacks the neighboring unsaturated carbon to form epoxide containing an
allylic radical (epoxyallylic radical), or undergo β-scission to break a carbon
bond and form an aldehyde together with an allylic radical, although the
former pathway is favored. The beta-scission products account for less than
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5% of the products. Another observation from the same group is that very
little alcohol is formed, which means most of the alkoxyl radicals don’t stay
long enough to abstract hydrogen from other molecules, instead, they tend
to form epoxyallylic radicals, which are much more stable than the alkoxyl
radicals.
1.5.3 Dihydroperoxide formation

Figure 1.8. Hock rearrangement via dihydroperoxide formation from
5(S)-HPETE

The scheme shown in Figure 1.8 was originally proposed by the Blair group
(36). There is no direct evidence for the formation of the dihydroperoxide,
but there was one indirect piece of evidence to support this mechanism.
Three products, 4-hydroperoxy-2-nonenal (HPNE), ONE and 5,8-dioxo-6(E)-
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octenoic acid were detected as their corresponding 2’-deoxyguanosine
adducts.

Figure 1.9: Direct hock-cleavage from 9(S)-HPODE and 2-step
dihydroperoxide formations from 13(S)-HPODE. This figure is modified
from (37)

The mechanism shown in Figure 9 was originally proposed by the Brash
group

to

explain

generated

why

racemic

enantiomerically

9(S)-hydroperoxyoctadecadienoic
4-HPNE,

pure

whereas

4(S)-HPNE

(37).

acid

13(S)-HPODE
The

(HPODE)
generated

9(S)-HPODE

has

a

hydroperoxide attached to C9 and also a conjugate double bond next to this
C9

carbon,

which

facilitates

the

vinyl

migration

during

the

Hock-

rearrangement. In the case of 13(S)-HPODE, the direct Hock-rearrangement
product was also observed, but to generate HPNE, another hydroperoxide
group must be first formed at C10. However, the Brash group subsequently
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synthesized the dihydroperoxide intermediate, 10,13-dihydroperoxy-HPODE,
and showed that no HPNE could be detected from this intermediate under
autoxidation condition. In contrast, under acidic conditions, HPNE formation
could be observed. This indicated that conjugated diene group was a better
migratory group compared to vinyl group during the Hock-rearrangement. In
order to explain these finding, the Brash group proposed an alternative
mechanism (37,38). This involved the formation of trimers or oligomers
derived from 15(S)-HPETE (Figure 1.10).
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Figure 1.10: Proposed trimer and oligomer formation during 15(S)HPETE decomposition (38).

1.6

Effects of AA-derived electrophiles on proteins and DNA

1.6.1 Carboxylic acid containing-electrophiles.
As discussed previously, carboxylic acid containing-electrophiles such as 15dPGJ2 (downstream metabolite of PGD2) can be formed from enzymatic
pathways. All of these electrophiles contain an α-β unsaturated ketone and
so

can

potentially

react

with

proteins,

GSH

or

DNA.

The

possible

detoxification pathways are to reduce the conjugated ketone or the double
bond to undergo GST-mediated conjugation with GSH. The metabolites are
then secreted from the cells. These carboxylate-containing α,β-unsaturated
ketone metabolites can have significant biological effects before they degrade.
For example, 15d-PGJ2 is a ligand for the peroxisome proliferator-activated
receptor gamma (PPAR) receptor and once 15d-PGJ2 binds to PPAR it
translocates from the cytosol into the nucleus. The PPARγ then binds to DNA
and regulates the transcription of target genes. The up- or down-regulation
of these genes can activate adipocyte differentiation, reduce inflammation
and also have anti-proliferation effects. (4)
1.6.2 Non-carboxylic acid containing-electrophiles.
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As discussed previously, aldehydes that are generated by lipid oxidation such
as MDA, HNE and ONE are bifunctional electrophiles that can react with
numerous cellular targets. The effects of these aldehydes on modifying
proteins, DNA and GSH have been intensively studied as described below.
1.6.2.1 Modification of proteins:
Lipid peroxidation generated electrophiles tend to modify proteins through
covalent

conjugation

with

cysteine,

histidine,

and

lysine

residues.

Immunostaining measured protein adducts from glycoxidation, lipid oxidation,
and acrolein has been analyzed in healthy subjects or patients with diabetic
nephropathy (DN) or with IgA nephropathy (IgA-N) (Table 1.2) (39). This
study clearly showed that the lipid oxidation products, MDA and HNE form
proteins adducts in DN or IgA subjects, while there are only trace adducts in
healthy subjects, which highlights the relationship between lipid oxidation
and DN or IgA nephropathy development.

Table 1.2 Results of immunostaining for glycoxidation products, lipid
oxidation products, and acrolein-protein adduct in healthy subjects
and patients with diabetic nephropathy (DN) or IgA nephropathy
(IgA-N). CML, carboxymethyllysine; MDA-lysine, malondialdehyde-lysine;
HNE-Protein, 4-hydroxy-nonenal-lysine.
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HNE generated from COX-mediated AA oxidation can even up-regulate the
expression of COX-2, and function as a positive feedback loop, which further
increases COX-2 products, resulting in “carbonyl stress” and oxidative stress.
(40)
1.6.2.2 Modifications of DNA:
2’-Deoxynucleosides (except thymidine) have primary amine groups, which
are good nucleophiles and could be the targets of electrophiles. The reactions
of different lipid oxidation-derived electrophiles with 2’-deoxyguanosine
(dGuo) and 2'-deoxyadenine (dAdo) are shown in Figure 1.11 (41). It has
been reported that dGuo adducts are detected in vivo at higher levels than
dAdo and 2’-deoxycytidine (dCyd) adducts. ONE and HNE DNA adducts can
only come from lipid oxidation, while MDA can arise from other sources such
as during thromboxane A2 biosynthesis. Therefore, ONE- and HNE-derived
DNA-adducts are good biomarkers for lipid oxidation. Normally, cells have an
efficient DNA repair system, and once damaged DNA is recognized, they
either remove the damaged oligonucleotides (nucleotide excision repair, NER)
or only the damaged bases (base excision repair, BER). The excised
damaged oligonucleotides or bases would be excreted, and it might be
possible to detect them in urine. Thus, the HNE and ONE modified
oligonucleotides or bases could potentially be lipid oxidation and DNA
damage biomarkers. These DNA adducts are mutagenic if not repaired, they
would accumulate and could be ultimately responsible for tumorigenesis.
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Figure 1.11, Scheme of dGuo or dAdo adducts from ONE, HNE, MDA
and trans-4,5-epoxy-2(E)-decenal (EDE) (41).

1.6.2.3 Inactivation of HNE
Similar to the inactivation of carboxylate-containing electrophiles, the
aldehyde moiety of HNE is also subject to reduction to an alcohol by aldoketo reductases (AKRs), particularly the AKR1B subfamily isoenzyme:
AKR1B1. Moreover, HNE is also the substrate of GSTs (42), which catalyze
the addition of GSH (Figure 1.12). Conjugation can also occur directly
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through a chemical reaction in the absence of GSTs. Thus, measurement of
HNE-GSH adduct could be strategy to monitor the lipid peroxidation level.

Figure 1.12 The detoxification of HNE by GST and AKR. Modified from
(42)

1.7

Brief description of mass spectrometry (MS) methods
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1.7.1 Three components:
All mass spectrometers have three components, an ion source, an analyzer
and a detector.
The most widely used ion source uses atmospheric pressure ionization (API),
which is usually coupled with liquid chromatography (LC). Analytes are
charged in solution by adjusting the pH of the mobile phase.

They are

allowed to evaporate from the liquid mobile phase into the gas phase
(electrospray ionization, ESI) or by applying a charged needle under
atmospheric pressure (atmospheric pressure chemical ionization, APCI). High
temperature (200 to 400 °C) and nitrogen gas help the desolvation process.
The mass analyzer is used to distinguish ions with different mass to charge
ratios (m/z). The ability of the mass spectrometer to distinguish ions of
different m/z depends upon the resolving power of the mass spectrometer
that is used.

The definition of resolution is the minimum m/z peak

separation divided by m/z. For high resolution, such as the LTQ-Orbitrap
(Thermo Electron, San Jose, CA), it could be up to 150,000, which means
that it would be possible to distinguish two ions that differ in mass by only
0.001 Da. In contrast, low resolution instruments, which typically operate at
unit mass resolution, can only distinguish two ions that differ in mass by 0.1
Da. Low resolution mass spectrometers include triple stage quadrupole (TSQ)
and linear ion trap (LTQ) instruments. TSQs are normally used for
quantitative studies, while ion traps are more widely used for structure
elucidation due to its multiple fragmentation function.
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1.7.2 TSQ quantitation:

Figure 1.13 A simplified example of how the TSQ separates peptide
ions with different m/z values.
The TSQ instrument has three quadrupoles (Q) in serial. Q1 and Q3 can work
in scanning mode, where all of the ions are allowed to pass through and
recorded by detector, while Q2 is designed to function as a collision cell,
which means the voltage and collision gas will apply to this cell and fragment
the ions coming from Q1. The most frequently applied mode with the TSQ is
selected reaction monitoring (SRM). Under this mode, Q1 is responsible for
allowing only a selected parent ion to pass through, while in Q2, this ion is
fragmented and only selected product ion is allowed to fly to Q3 and
recorded. (MRM usually refers to multiple product ions from a single parent
ion). LC-SRM/MS is highly selective even with only unit resolution because
specificity is conferred by the fragmentations process.

The method is also

highly sensitive and reproducible. Thus, this LC-SRM/MS is widely used in
lipid metabolite and quantification.
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Chapter 2 11-Oxo-Eicosatetraenoic Acid is a
Cyclooxygenase-2/15-Hydroxyprostaglandin
Dehydrogenase-Derived Anti-Proliferative Eicosanoid

2.1 ABSTRACT
Previously, the Blair laboratory established that 11(R)-HETE was a significant
COX-2-derived AA metabolite in epithelial cells. Stable isotope dilution chiral
LC-electron capture atmospheric pressure chemical ionization (ECAPCI)/MS
was used to quantify COX-2-derived eicosanoids in the human colorectal
adenocarcinoma (LoVo) epithelial cell line, which expresses both COX-2 and
15-PGDH. 11(R)-HETE secretion reached peak concentrations within minutes
after AA addition before rapidly diminishing, suggesting further metabolism
had occurred. Surprisingly, 15-PGDH, which is normally specific for oxidation
of eicosanoid 15(S)-hydroxyl groups, was found to convert 11(R)-HETE to
11-oxo-ETE.

Furthermore, LoVo cell lysates converted 11(R)-HETE to 11-

oxo-ETE and inhibition of 15-PGDH with 5-[[4-ethoxycarbonyl) phenyl]azo]2-hydroxy-benzeneacetic acid (CAY 10397) (50 µM) significantly suppressed
endogenous 11-oxo-ETE production with a corresponding increase in 11(R)HETE.

These data confirmed COX-2 and 15-PGDH as enzymes responsible

for 11-oxo-ETE biosynthesis. Finally, addition of AA to the LoVo cells resulted
in rapid secretion of 11-oxo-ETE into the media, reaching peak levels within
20 min of starting the incubation. This was followed by a sharp decrease in
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11-oxo-ETE levels. GST was found to metabolize 11-oxo-ETE to the 11-oxoETE-GSH (OEG)-adduct in LoVo cells, as confirmed by LC-MS/MS analysis.
Bromodeoxyuridine (BrdU)-based cell proliferation assays in human umbilical
vein endothelial cells (HUVECs) revealed that the half-maximal inhibitory
concentration (IC50) of 11-oxo-ETE for inhibition of HUVEC proliferation was
2.1 µM.

These results show that 11-oxo-ETE is a novel COX-2/15-PGDH-

derived eicosanoid, which inhibits endothelial cell proliferation with a potency
that is similar to that observed for 15d-PGJ2.
2.2 INTRODUCTION
In an earlier study, the Blair laboratory established that 11(R)-HETE was a
significant COX-2-derived AA metabolite in epithelial cells (43). However, the
consequences of this finding were not clear at that time. A number of toxic
substances including arsenite (44), dioxin (45) benzo[a]pyrene-diol-epoxide
(46), and cigarette smoke (47) up-regulate COX-2 expression, which in turn
regulates numerous intracellular biochemical pathways. This occurs primarily
through the biosynthesis of COX-2-derived AA metabolites, which can exert
cell-specific effects on inflammation, cell growth, and proliferation. For
example, COX-2-derived prostaglandin (PG) E2 increases tumor proliferation
through multiple mechanisms including activation of plasma membrane Gprotein-coupled receptors and the nuclear peroxisome proliferator-activated
receptor (PPAR).(48)
Steady-state levels of PGE2 are maintained by PGE-synthase-mediated
biosynthesis from COX-2-derived PGH2 and catabolism by 15-PGDH-mediated
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inactivation to 15-oxo-PGE2 (Figure 2.1).(49,50) The 15-oxo-PGE2 is then
converted

to

reductase.(51)

13,14-dihydro-15-oxo-PGE2

by

15-oxo-prostaglandin-13

Loss of 15-PGDH expression is associated with tumor

formation in bladder, breast, colon, intestine, kidney, lung, pancreas,
stomach, and skin cancer.(49,50,52-54) Thus, up-regulation of COX-2 (48)
and down-regulation of 15-PGDH (52) provides a switch towards endogenous
mediators that are significant contributors to cancer progression.(57)
PGD2, another COX-2-derived metabolite, is also metabolized by 15-PGDH to
form 15-oxo-PGD2, which is then converted to the corresponding inactive
13,14-dihydro-derivative (Figure 2.1).(58) Alternatively, PGD2 undergoes
albumin-mediated

dehydration

to

give

PGJ2,

followed

by

a

further

dehydration to give 15-deoxy-12,14-prostaglandin J2; (15d-PGJ2) (Figure
2.2).(59) Previous studies have shown that 15d-PGJ2 is a PPAR agonist,(60)
which inhibits HUVEC proliferation in culture.(61) In addition, 15d-PGJ2 can
induce caspase-mediated endothelial cell apoptosis(62) and inhibit the
nuclear factor κB (NFB) pathway.(63-64) It can also increase levels of p53
in HUVECs, activate p53 phosphorylation, and induce p21.(65)
Studies of purified COX enzymes have shown that 11(R)-HETE, 15(S)-HETE,
and 15(R)-HETE are the major HETEs that are formed.(66) The HETEs arise
from reduction of the corresponding HPETEs primarily through the peroxidase
(POX) activity of COXs (Figure 2.1).(67) 11(R)-HETE was a significant
eicosanoid secreted by AA-treated rat intestinal epithelial cells that stably
express COX-2 (RIES cells) but it was rapidly metabolized.(43) 15(S)-HETE
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was formed in lower abundance and metabolized to 15-oxo-ETE (66,68) as
expected from its 15(S)-configuration and the substrate specificity of 15PGDH. 15-Oxo-ETE was also found to inhibit endothelial cell proliferation,
although at concentrations higher than 15d-PGJ2.(68) However, there is little
evidence

that

15d-PGJ2

can

be

formed

in

vivo

at

concentrations

commensurate with an endogenous anti-proliferative role.(69) In our earlier
study, (43) the metabolic fate of 11(R)-HETE secreted by the RIES cells was
not established. 11-Oxo-ETE has now been synthesized and a LC-selected
reaction monitoring (SRM)/MS method for its analysis has been developed.
This has made it possible to determine whether 11-oxo-ETE is secreted by
human epithelial cell lines with up-regulated COX-2 expression and to
identify the dehydrogenase responsible. The ability of 11-oxo-ETE to
modulate HUVEC proliferation has also been examined.
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Figure 2.1. Formation and action of COX-2-derived eicosanoids in
epithelial cell models. AA is released from membrane phospholipids by
calcium-dependent cytosolic phospholipase A2 (cPLA2). The released AA
undergoes COX-2-medaited metabolism to PGs or forms the lipid
hydroperoxides, 15(S)-hydroperoxyeicosatetraenoic acid; (HPETE), 15(R)HPETE and 11(R)-HPETE, which are reduced to the corresponding HETEs.
PGD2 and PGE2 are inactivated by 15-PGDH-mediated conversion to their 15oxo-metabolites.
Both 15-oxo-PGD2 and 15-oxo-PGE2 are converted to
13,14-dihydro-5-oxo-PG metabolites. Intact PGD2 secreted by the epithelial
cells can undergo albumin-mediated dehydration to 15d-PGJ2. PGE2 secreted
from the epithelial cells by the ABCC4 transporter is pro-proliferative for
tumor cells. Re-uptake of PGE2 by OATP2A1 into the epithelial cells leads to
further 15-PGDH-mediated inactivation. In contrast to PGE2 and PGD2,
15(S)-HETE and 11(R)-HETE are activated by 15-PGDH-mediated oxidation
to 15-oxo-ETE and 11-oxo-ETE, respectively. The oxo-ETEs are further
conjugated to form OEGs. Secreted 15- and 11-oxo-ETE that escape further
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metabolism can then inhibit endothelial cell proliferation. Therefore, downregulation of 15-PGDH and OATP2A1 would result in increased PGE2mediated tumor and endothelial cell proliferation.

O

11
HO

9 8
12

6

5

9
CO2H

14

15 C5H11
OH

11
O

8
12

8

6 5

5
CO2H

14 15

C5H11

15d-PGJ2

PGE2
9

6

9

8

6 5

CO2H

15 C5H11
11 12 14 O
15-oxo-ETE

CO2H

14 15
11
C5H11
O 12
11-oxo-ETE

Figure 2.2. Chemical structures of COX-2 derived eicosanoids.

2.3 EXPERIMENTAL PROCEDURES
2.3.1 Chemicals and Reagents.
AA (peroxide-free), 11(R,S)-HETE, 15(R,S)-HETE, [2H8]-15(S)-HETE, [13C20]15-oxo-ETE, 15-oxo-ETE, PGE2, [2H4]-PGE2, 13,14-dihydro-15-keto-PGE2,
[2H4]-13,14-dihydro-15-keto-PGE2, 15d-PGJ2, CAY10397, protease inhibitor
cocktail and recombinant human 15-PGDH were purchased from Cayman
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(Ann Harbor, MI).

The Dess-Martin reagent [1,1,1-Tris(acetyloxy)-1,1-

dihydro-1,2-benziodoxol-3-(1H)-one],

2,3,4,5,6-pentafluorobenzyl

(PFB)

bromide, Trizma-HCl, lipoxidase from Glycine max (soybean), sodium
borohydride, and NAD+ were purchased from Sigma-Aldrich (St. Louis, MO).
Fetal bovine serum (FBS) was from Gemini Bioproducts (West Sacramento,
CA). F12K medium, DMEM medium, Medium 200 (M200), Minimum Essential
Medium (MEM), D-glucose, L-glutamine, low-serum growth supplement
(LSGS) kit, penicillin, and streptomycin were supplied by Invitrogen
(Carlsbad,

CA).

LC-MS

grade

water,

hexane,

methanol,

isopropanol,

acetonitrile and dichloromethane were obtained from Fisher Scientific
(Pittsburgh, PA).

Gases were supplied by The Linde Group (Munich,

Germany). [13C20]-AA was obtained from Spectra Stable Isotopes (Columbia,
MD).
2.3.2 Cell Culture.
Human colorectal adenocarcinoma LoVo cells (ATCC, Manassas, VA) were
cultured in F12K medium supplemented with 10% FBS, 2 mM/L glutamine,
100,000 units/l penicillin and 100 mg/l streptomycin. Human colonic
adenocarcinoma HCA-7 Colony 29 cells (Sigma-Aldrich, St. Louis, MO) were
grown in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 110 mg/L
sodium pyruvate, 100,000 units/l penicillin and 100 mg/l streptomycin. For
lipidomics analysis, the culture media was replaced with serum-free F12K or
DMEM media before the treatment. HUVECs were obtained from Invitrogen
(Carlsbad, CA), and cultured on collagen I-coated tissue culture dishes in

34

Medium 200 supplemented with LSGS kit. Caco-2 cells were grown in MEM
containing 20% FBS 2 mM/L glutamine, 100,000 units/l penicillin and 100
mg/l streptomycin. Cell proliferation assays were performed using HUVECs
from passage 4.
2.3.3 Mass Spectrometry.
A triple stage quadrupole (TSQ Quantum) mass spectrometer (Thermo
Electron, San Jose, CA) equipped with an APCI source was used for the
quantitative lipidomics analyses. Targeted chiral LC-ECAPCI/SRM/MS analysis
was conducted using PFB derivatives of 7 lipids and 4 heavy isotope analog
internal standards. For the lipidomics profile, the instrument was operated in
the negative ion mode, and unit resolution was maintained for both precursor
and fragment ions.

Operating conditions for the TSQ Quantum were:

vaporizer temperature at 450°C; heated capillary temperature at 250 °C with
the corona discharge needle set at 30 µA; nitrogen as sheath (25 psi) and
auxiliary (5 arbitrary units) gas. Collision-induced dissociation (CID) was
performed using argon as the collision gas at 2.7 mtorr in the RF-only
quadrupole. The following SRM transitions were used: 11-oxo-ETE-PFB, m/z
317 → 165 (collision energy (CE), 25 eV), 15-oxo-ETE-PFB, m/z 317 → 113
(CE, 18 eV), [13C20]-15-oxo-ETE-PFB, m/z 337 → 120 (CE, 18 eV), 11(R)HETE-PFB, m/z 319 → 167 (CE, 16 eV), [2H8]-15(S)-HETE-PFB, m/z 327 →
226 (CE, 13 eV), PGE2-PFB, m/z 351 → 271 (CE, 18 eV), [2H4]-PGE2-PFB,
m/z 355 → 275 (CE, 18 eV). 13,14-dihydro-15-keto-PGE2-PFB, m/z 351 →
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235 (CE, 22 eV), [2H4]-13,14-dihydro-15-keto-PGE2-PFB, m/z 355 → 239 (CE,
22 eV).
For GSH adduct analysis, the mass spectrometer was operated in the positive
ion mode with an electrospray ionization (ESI) source.

The operating

conditions were: spray voltage at 4 kV; capillary temperature at 350°C;
nitrogen as sheath (35 psi) and auxiliary (13 arbitrary units) gas. CID was
performed using argon as the collision gas at 2.7 mtorr in the Rf-only
quadrupole. The following SRM transition (m/z 626 → 497) was monitored
for 11-oxo-ETE-GSH (CE, 18 eV).
2.3.4 Liquid Chromatography.
LC separations were conducted using a Waters® Alliance 2690 HPLC system.
A Chiralpak AD-H column (250 × 4.6 mm inner diameter, 5 µm; Daicel) was
employed for normal phase separation (flow-rate 1 ml/min) of PFBderivatives of eicosanoids.

Gradient 1 was used for separating PFB-

derivatives of HETEs and PGE2, whereas gradient 2 was used for PFB
derivatives of oxo-ETEs. For gradient 1, solvent A was hexane, and solvent B
was methanol/isopropanol (1:1; v/v). Gradient 1 was as follows: 2% B at 0
min, 2% B at 3 min, 3.6% B at 11 min, 8% B at 15 min, 8% B at 27 min, 50%
B at 30 min, 50% at 35 min, and 2% B at 37 min.

Separations were

performed at 30°C using a linear gradient. For gradient 2, solvent A was
hexane, and solvent B was isopropanol/hexane (6:4; v/v). Gradient 2 was as
follows: 2% B at 0 min, 2% B at 14.5 min, 12% B at 15 min, 23% B at 19
min, 90% B at 19.5 min, 90% B at 23.5 min, and 2% B at 24 min.
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A Chiralpak AD-RH column (150 × 4.6 mm inner diameter, 5 µm; Daicel)
was used for reverse phase (isocratic method 1, flow-rate 0.5 ml/min)
separation of the un-derivatized 11-oxo-ETE. The mobile phase for isocratic
separations was methanol/water/formic acid (95:5:0.1; v/v).
Chemically synthesized 11-oxo-ETE was purified by normal-phase (isocratic
method 2) preparative LC (Ultrasphere™ 250 × 10 mm, inner diameter, 5
µm; Beckman) using Hitachi LC system by monitoring the UV absorbance at
236 nm. The mobile phase for isocratic method 2 (flow-rate 2.5 ml/min) was
hexane/isopropanol/acetic acid (98.5:1.5:0.1; v/v).
GSH adducts were separated by reverse phase using gradient 3 on Waters®
Alliance 2690 HPLC system. The separation employed a Phenomenex Synergi
Hydro-RP column (150 × 4.6 mm inner diameters, 5 µm). Solvent A was 0.1%
aqueous formic acid, and solvent B was methanol/acetonitrile (50:50; v/v).
Gradient 3 was as follows: 2% B at 0 min, 2% B at 14 min, 30% B at 20 min,
42% B at 21 min, 65% B at 27 min, 80% B at 29 min, 90% B at 33 min, 90%
B at 34 min, 2% B at 35 min. The flow rate was 0.4 ml/min. The separation
was performed at ambient temperature using a linear gradient.
2.3.5 PFB Derivatization.
Eicosanoids were dissolved in 100 µl of acetonitrile, and then reacted with
100 µl of PFB bromide

in acetonitrile

(1:19;

v/v) and 100 µl of

diisopropylethylamine in acetonitrile (1:9; v/v) at room temperature for 30
min. The derivatives were evaporated to dryness, dissolved in 100 µl of
hexane/ethanol (95:5; v/v) and analyzed by chiral LC-ECAPCI/SRM/MS.
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2.3.6 Enzymatic Conversion of 11(R)-HETE by 15-PGDH.
Various concentrations of 11(R)-HETE (0, 2.3 M, 4.6 M, 6.9 M, 9.2 M
and 23 M) were incubated with 4 nM of recombinant human 15-PGDH (50
ng, 1.8 pmol) and cofactor NAD+ (400 M) in 50 mM Tris-Cl (pH 7.9) for 3.5
min at 37

o

C.

Each total reaction volume was 200 l. After a 3.5 min

incubation, the enzymatic reaction was quenched with 400 l of ice cold
methanol and [13C20]-15-oxo-ETE (8 ng) added as the internal standard.
Eicosanoids were extracted with 1.2 ml of dichloromethane/methanol (8:1;
v/v). The lower organic layer was then evaporated to dryness under nitrogen
and reconstituted in methanol (100 l). An aliquot (25 µl) was separated
using isocratic method 1 and analyzed by LC-ESI/MS as described above. The
retention time for 11-oxo-ETE was 8.7 min. In separate experiments, the
formation of 11-oxo-ETE was found to be linear for the first 5 min.
Eicosanoids were quantified by interpolation from a standard curve prepared
with 11-oxo-ETE using [13C20]-15-oxo-ETE as the internal standard.
2.3.7 Chemical Synthesis and Purification of 11-Oxo-ETE.
The Dess-Martin reagent (5 mg, 12.0 mol) was added to a solution of
11(R,S)-HETE (10 mg, 31.0 µmol) in dichloromethane (0.5 ml) and stirred
for 2 h at room temperature. The reaction was monitored by LC-MS using
gradient 1 as described above, after PFB derivatization until there was no
starting

material

left.

There

was

only

one

major

product,

which

corresponded to 11-oxo-ETE. The reaction mixture was centrifuged twice at
3,400 rpm (10 min) and the supernatant was evaporated. The residue was
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dissolved in the mobile phase (800 l) and purified by isocratic method 2 as
described above. The retention time for 11-oxo-ETE was 13.1 min.

High

resolution accurate mass measurements were obtained using electrospray
ionization on a Thermo LTQ-FT mass spectrometer at a resolution of 100,000
(data not shown). NMR spectra were obtained on a Bruker 500 MHz NMR
instrument.
2.3.8 15-PGDH inhibition in LoVo or HCA-7 Cell Lysates by CAY10397.
LoVo or HCA-7 cells were grown to 90% confluence, washed with 10 ml of
phosphate-buffered saline (PBS) buffer (2 times), and then gently scraped in
600 µl of lysis buffer containing 0.1 M Tris-HCl (pH 7.9) and the protease
inhibitor.

Cell suspension was transferred to 2 ml Eppendorf tubes, and

sonicated for 60 seconds on ice (power 5). Cell lysate was then incubated
with or without the selective 15-PGDH inhibitor (CAY10397, 50 M) and its
co-factor (NAD+, 500 µM) for 10 min at 37°C. The pH was then adjusted to
4 with 10% aqueous acetic acid (10 µl) followed by addition of the internal
standard mix, [13C20]-15-oxo-ETE, [2H8]-15(S)-HETE and [2H4]-PGE2 (50
pg/µl, 20 µl). Diethyl ether (600 µl) was added, and samples were vortexmixed and centrifuged (15000 rpm×2 min). The organic layer was
evaporated under nitrogen, and then the eicosanoids were derivatized with
PFB bromide as mentioned above. Finally, samples were re-dissolved in
hexane/ethanol (95:5; v/v, 100 µl), and analyzed (20 µl) by normal phase
LC-ECAPCI/MS.

The amounts of eicosanoids were normalized by protein

concentrations of each lysate, which were determined by BCA assay.
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2.3.9 Metabolism of AA by LoVo or HCA-7 Cells.
LoVo or HCA-7 cells were grown to 90% confluence in 6-well plates as
described above, and then fed fresh serum-free F-12K or DMEM medium.
Cells were then incubated with AA (10 µM) for 0, 5, 10 and 30 min, 1 and 2.5
h at 37°C. At each time point, 0.6 ml medium was taken out, 20 µl 10%
aqueous acetic acid was added to adjust pH to 3-4, together with 20 µl
internal standards mixture (50 pg/ µl [12C20]-15-oxo-ETE, [2H8]-15(S)-HETE,
[2H4]-PGE2 and [2H4]-13,14-dihydro-15-keto-PGE2-PFB).

Then diethyl ether

(1 ml) was added, and the mixture was vortex-mixed and centrifuged (15000
rpm × 2 min). The upper ether layer was evaporated under nitrogen, and
PFB derivatives were synthesized as described above and analyzed by normal
phase LC-ECAPCI/MS.
2.3.10 Standard curves for Eicosanoid Quantification.
To quantify eicosanoids excreted in the medium, Eppendorf tubes containing
0.6 ml F12K medium were spiked with lipid standards, together with internal
standards for ([12C20]-15-oxo-ETE, [2H8]-15(S)-HETE ,[2H4]-PGE2 and [2H4]13,14-dihydro-15-keto- PGE2-PFB 1 ng each). To quantify eicosanoids in the
cell lysate, lipids standards and internal standards mixture were spiked into
0.2 ml Tris-HCl buffer. The extraction and PFB derivatization methods are the
same as mentioned above.
2.3.11 Analysis of 11-OEG adducts in LoVo cell lysate.
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LoVo cells were grown to 90% confluence and then washed with PBS (10 ml).
Cells were gently scraped in 600 µl Tris-HCl buffer (0.1 M, pH=7.9),
containing protease inhibitor. Cell lysates were transferred to 2 ml Eppendorf
tubes, and sonicated for 60 seconds on ice (power 5). 11-oxo-ETE (20 ng in
ethanol) was added to the lysate together with 1 mM GSH. After incubation
for 25 min at 37°C, 10 µl of 10% acetic acid was added, and the sample was
loaded onto SPE column (oasis HLB, 30 mg) pre-conditioned with methanol
and then 0.1% formic acid. The column was washed with 1 ml water and
eluted with 250 µl methanol, and then 20 µl was analyzed by reverse phase
LC-ESI/MS using gradient 3, as described above.
2.3.12 Conversion of 11-oxo-ETE and 15-oxo-ETE to 11(S)-HETE and
15(S)-HETE in Caco-2 cell lysate.
Caco-2 cell lysate was prepared in the same way as LoVo cell lysate, and
then NADH (100 M), NADPH (100 M), 11-oxo-ETE (100 nM) and [13C20]-15oxo-ETE (100 nM) were added. For the control sample, no oxo-ETEs were
added. The mixtures were kept at 37 °C for 10 min before lipid extraction.
The extraction and PFB derivatization procedures were the same as described
above.
2.3.13 Cell proliferation assay.
BrdU incorporation in HUVECs was used to assess the effects of 11-oxo-ETE
on cell proliferation. The BrdU assay was performed in a 96-well format using
a commercially available colorimetric enzyme-linked immunosorbent assay
(ELISA) kit (Roche), and also by immunofluorescence microscopy. Equal
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numbers of HUVECs in passage 4 were plated in either, collagen-I coated 96well plates (2000 cells/well), or collagen-I coated 8-chamber tissue culture
glass slides (10000 cells/chamber). Cells were allowed to attach overnight in
0.25% DMSO containing media. Eicosanoids were dissolved in DMSO, such
that the final concentration of DMSO in cell media was always 0.25% or
lower. Cells were then treated for 24 h with either vehicle (0.25% DMSO),
11-oxo-ETE (1 nM-100 M), or 15d-PGJ2 (1 nM-100 M). After 18 h of
treatment, BrdU (final concentration, 10 M in 0.25% DMSO) was added to
each treatment group for an additional 6 h.
For the colorimetric ELISA, the manufacturer’s protocol was followed to
perform the assay. The absorbance at λ = 370 nm obtained from the assay
was transformed to the cell numbers using a standard curve constructed by
plating known number of HUVECs in triplicate. The IC50 values for eicosanoid
inhibition of HUVEC proliferation were defined as the half maximal inhibitory
concentration for endothelial cell proliferation over 24 h when compared with
vehicle-treated cells. They were determined from the regression lines of the
log inhibitor vs. response curves using a least squares fit.
For the immunofluorescence staining, cells were fixed with neutral buffered
formalin for 10 min, permeabilized with methanol for 20 min, and then DNA
was denatured by pressure cooking the slides in 10 mM citric acid buffer, pH
6 for 1 h. Cells were then incubated overnight with rat anti-BrdU antibody
(1:1000, Accurate Chemical & Scientific Corp.) at 4°C, followed by 30 min
incubation at 37 °C with Cy3-conjugated donkey anti-rat secondary antibody
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(1:600, Jackson Immuno Research).

Cells were counterstained with 4',6-

diamidino-2-phenylindole (DAPI, Invitrogen) and visualized using a Nikon
E600 microscope equipped with differential interference contrast (Nomarski)
optics and photographed (x200 magnification) with a Fast 1394 QICam
(QImaging). Positive BrdU staining was quantified by image analysis using
IVision Analysis Software (Biovision). The percentage of proliferating cells
was determined by counting the BrdU-positive cells versus the total number
of cells in randomly selected microscopic fields (10/replicate) for each
treatment group.
Statistical Analyses. All experiments were conducted in triplicate, unless
otherwise indicated. Statistical significance (p value < 0.05) was determined
using a two-tailed unpaired t-test employing GraphPad® Prism software (v
5.01).

2.4 RESULTS
2.4.1 Biosynthesis of 11-oxo-ETE by 15-PGDH.
Various concentrations of 11(R)-HETE were incubated with recombinant
human 15-PGDH and NAD+ at 37 °C. A Michaelis-Menten kinetic analysis of
11-oxo-ETE formation revealed that the Vmax (296 nmol/min/mg), Km (3.42
M), and kcat (8.6 min-1) values for oxidation of 11(R)-HETE (Figure 2.3) were
similar to those for 15(S)-HETE (Km = 1.65 M, kcat =8.6 min-1;). Therefore,
the catalytic efficiency (Kcat/Km) for 15-PGDH-mediated oxidation of 11(R)-

43

HETE (2513 min-1mM-1, Figure 2.3) was similar to that for 15(S)-HETE (7091
min-1mM-1;).
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Figure 2.3. Kinetic plot of the formation of 11-oxo-ETE and 15-oxoETE by 15-PGDH. Various concentrations of 11(R)-HETE or 15(S)-HETE (023 M) were incubated with 4 nM 15-PGDH and cofactor NAD+.
Determinations for 11-oxo-ETE were conducted in triplicate (means ± S.E.M.)
by stable isotope dilution LC-ESI/MS analyses.

2.4.2 Chemical Synthesis of Authentic 11-oxo-ETE.
11-Oxo-ETE was synthesized chemically by oxidizing racemic 11(R,S)-HETE
using the Dess-Martin reagent, and then purified using chromatographic
separation. A combined total of 10 mg of the racemic 11(R,S)-HETE resulted
in the isolation of 4.9 mg of pure 11-oxo-ETE (overall yield of 49%). High
resolution electrospray ionization-MS of 11-oxo-ETE revealed accurate
masses of m/z 319.2263 and m/z 341.2079 for the protonated and sodiated
molecules, respectively [calculated accurate mass for protonated (C20H31O3)
and sodiated (C20H30O3Na) molecules, m/z 319.2273 and m/z 341.2093,
respectively]. 500 MHz 1H-NMR (H, CDCl3;) 7.55 (dd, J1 = 11.5 Hz, J2 =15.5,
1H), 6.21(d, J =15.5Hz, 1H), 6.15-6.11 (m, 1H), 5.97-5.92 (m, 1H), 5.605.58 (m, 2H), 5.41-5.38 (m, 2H), 3.35 (d, J =4.5Hz, 2H), 2.83-2.81 (m, 2H),
2.38-2.31 (m, 4H), 2.17-2.12 (m, 2H), 1.74-1.25 (m, 8H), 0.89 (t, J = 7.0
Hz, 3H).

Analysis of purified 11-oxo-ETE as its PFB derivative by LC-

ECAPCI/MS (Figure 2.5a) revealed an intense negative ion at m/z 317
corresponding to [M-PFB]-. CID of [M-PFB]- (m/z 317) and MS/MS analysis
revealed major product ions at m/z 273, 219, 165, 149, and 123. The UV
spectrum was consistent with the presence of a conjugated dienone with a
UV max at 279 nm and molecular extinction coefficient () of 18,985 M-1cm-1.
The NMR spectrum data is shown in Figure 2.4.
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Figure 2.4 500 MHz 1H NMR spectrum of 11-oxo-ETE in CDCl3.
2.4.3 Confirmation of 11-oxo-ETE Identity by LC-MS and MS/MS
Analyses.
The LoVo cell line is known to express both COX-2 and 15-PGDH and only
trace amounts of COX-1,(52,60) this was confirmed by Western blot analysis
(data not shown). Cell lysates were incubated with 100 nM 11(R)-HETE in the
presence of 500 M NAD+ for 10 min. LC-MS analysis of PFB derivatives of
eicosanoids extracted from the LoVo cell lysate showed that there was a
single major metabolite, which eluted at 12.8 min (data not shown). The full
scan mass spectrum of this metabolite had only one major ion at m/z 317
corresponding to [M-PFB]- (Figure 2.5b). CID and MS/MS analysis revealed
the formation of intense product ions at m/z 123, 149, 165, 219, and 273
(Figure 2.5b).

The product ion spectrum was identical with that obtained
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from authentic synthetic 11-oxo-ETE-PFB (Figure 2.5a), which confirmed the
identity of 11-oxo-ETE from LoVo cells. The product ion at m/z 165 in LoVo
cell-derived

and

synthetic

11-oxo-ETE-PFB

corresponded

to

cleavage

between C-9 and C-10 and m/z 123 was formed from cleavage between C-11
and C-12 (Figure 2.5).

9

165

(a)

273
COO

8
12

Relative abundance (%)

100

123
m/ z 317 (M-PFB-)

80

149.0

60

C5H11

11
O

165.0

219.0

123.0
40

273.0
20

317.0

0
100

150

9

149.0

40

273
COO

8

C5H11

11
O

80

219.0

60

300

12

165.0

100

250

m/z

165

(b)

Relative abundance (%)

200

123
m/ z 317 (M-PFB-)
317.0

123.0
273.0

20

0
100

150

200

250

300

m/z
Figure 2.5. Confirmation of 11-oxo-ETE formation by LC-MS/MS
analysis. Specific product ions observed by CID and MS/MS analysis of [M47

PFB]∙ (m/z 317), corresponding to 11-oxo-ETE are shown on the relevant
chemical structures. (a) Synthetic 11-oxo-ETE-PFB standard; (b) 15-PGDHderived 11-oxo-ETE-PFB from LoVo cell lysate to which 100 nM 11(R)-HETE
had been added.

2.4.4 Separation of Eicosanoids by Chiral LC-ECAPCI/SRM/MS.
Lysates from LoVo cells were extracted for the eicosanoids, which were then
analyzed (after PFB derivatization) by LC-ECAPCI/SRM/MS. A representative
chromatogram (Figure 2.6) reveals the separation of 11-oxo-ETE (retention
time 12.8 min) and 15-oxo-ETE (retention time 12.0 min) that were formed
in the LoVo cell lysate. Additional eicosanoids that were observed (Figure 2.6)
include, 13,14-dihydro-15-keto-PGE2 (retention time, 33.6 min), 11(R)-HETE
(retention time, 10.0 min), and PGE2 (retention time, 29.4 min).
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Figure 2.6. Targeted chiral lipidomics analysis of COX-2 derived
eicosanoids from LoVo cells. LoVo cells were lysed; eicosanoids were
extracted, derivatized with PFB bromide, and analyzed by LCECAPCI/SRM/MS. LoVo cell lysates were pre-treated with 50 µM CAY10397
to inhibit 15-PGDH to be able to detect the 11-, 15-HETEs and PGE2.
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Representative chromatograms are shown for (a) 11(R)-HETE-PFB (m/z319
→167), (b) [2H8]-15(S)-HETE-PFB internal standard (m/z 327→226), (c) 11oxo-ETE-PFB (m/z 317→165), (c) 15-oxo-ETE-PFB (m/z 317→165), (d)
[13C20]-15-oxo-ETE-PFB internal standard (m/z 337→120), (e) PGE2-PFB (m/z
351→271), (f) [2H4]-PGE2-PFB (m/z 355→275), (g) 13,14-dihydro-15-oxoPGE2-PFB (m/z 351→235), (h) [2H4]-13,14-dihydro-15-oxo-PGE2-PFB (m/z
355→239).

2.4.5 Inhibition of 15-PGDH by CAY10397 in LoVo and HCA-7 cell
lysates.
In contrast to LoVo cells, the HCA-7 cell line is known to express COX-2 and
only trace amounts of COX-1 and 15-PGDH (52, 71). This was confirmed by
Western blot analysis (data not shown). LoVo (Figure 2.7a) or HCA-7 (Figure
2.7b) cell lysates were incubated with 500 M NAD+, with or without the 15PGDH-inhibitor, CAY10397 (50 µM) for 10 min. Inhibition of 15-PGDH
significantly abolished the formation of endogenous 11-oxo-ETE (Figure 2.7a)
by 92%, along with the diminished formation of 15-oxo-ETE as well as
13,14-dihydro-15-oxo-PGE2 (Figure 2.7a) in the LoVo cell lysate. However,
since the oxo-ETEs and 13,14-dihydro-15-oxo-PGE2 were undetectable in
HCA-7 cell lysate, their precursors were quantified instead, and CAY10397
had no effect on their levels (Figure 2.7b).
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Figure2.7. Inhibition of 15-PGDH in LoVo and HCA-7 cell lysates by
CAY10397. (a) LoVo or (b) HCA-7 cell lysate (1x106 cells/treatment group)
was incubated with or without CAY10397 (50 µM, to inhibit 15-PGDH).
Eicosanoids were extracted from the lysates and their levels were determined
by chiral LC-ECAPCI/SRM/MS. Analyses were performed in triplicates, and
error bars show S.E.M.
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2.4.6 Secretion of eicosanoids from LoVo and HCA-7 cells following
AA addition.
Time-course analyses for the amount of different eicosanoids secreted by
LoVo and HCA-7 cells following AA incubation for 0-2.5 h are shown in Figure
2.8a and Figure 2.8b, respectively. 11-Oxo-ETE was secreted into the cell
media by LoVo cells along with 15-oxo-ETE and 13,14-dihydro-15-oxo-PGE2
(Figure 2.8a). Interestingly, both 11-oxo-ETE and 15-oxo-ETE reached
maximum concentrations 10 min after the addition of AA to the cells. This
was followed by a decline of both eicosanoids to steady-state levels after 2.5
h (Figure 2.8a) in LoVo cells. In contrast, 13,14-dihydro-15-oxo-PGE2 levels
did not peak until 1 h after the addition of AA (Figure 2.8a) and remained
constant throughout the remainder of the incubation period.

In contrast,

none of the eicosanoids resulting from 15-PGDH-mediated metabolism were
detected in the media of HCA-7 cells incubated with AA (Figure 2.8b).
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Figure 2.8. Time course for eicosanoids secreted from LoVo and HCA7 cells following AA incubation. (a) LoVo or (b) HCA-7 cells were
incubated with 10 M AA for 0-6 h. The different eicosanoids secreted into
the media at various time-points were extracted and their levels were
determined by stable isotope dilution LC-ECAPCI/SRM/MS analysis of their
PFB derivatives. Determinations were conducted in triplicate (means ±
S.E.M.), and the quantitation was performed using the standard curves
generated for these eicosanoids.

2.4.7 Formation of 11-OEG in LoVo Cell Lysates.
Biosynthesis of 11-OEG was monitored in the cell lysate after the addition of
100 nM 11-oxo-ETE and 1 mM GSH to the LoVo cell lysate. 11-OEG formation
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was detected and confirmed by LC-MS/MS monitoring of the major
metabolite formed after a 30 min incubation. OEG (retention time, 32.2 min,
data not shown) was observed as an intense peak in the LC-ESI/MS
chromatogram when analyzed by gradient 3 (as described above). CID and
MS/MS analysis revealed the formation of intense product ions at m/z 497,
319, 308, and 179 (Figure 2.9).
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Figure 2.9. LC-MS/MS analysis of 11-OEG adduct.
11-OEG was
synthesized by reacting 200 nM 11-oxo-ETE and 1 mM GSH in LoVo cell
lysate for 25 min at 37°C. The product was extracted by solid-phase
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extraction and analyzed by LC-ESI/MS/MS. Specific product ions observed
by CID of [MH]+ (m/z 626) are shown with their relevant chemical structures
in the MS/MS analysis of 11-OEG.

2.4.8 Conversion of 11-oxo-ETE and 15-oxo-ETE to 11(S)-HETE and
15(S)-HETE in Caco-2 cell lysate.
Besides detoxification by GST/GSH pathway, oxo-ETEs can also be reduced
to their alcohol form. This biotransformation was tested in Caco-2 cells by
adding exogenous 11-oxo-ETE and [13C20]-15-oxo-ETE to the cells lysate,
together

with

potential

cofactor

NADH/NADPH.

After

analyzing

the

eicosanoids in the lysate, the formation of 11(S)-HETE and [13C20]-15(S)HETE was observed. The data are shown in Figure2.10.
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Figure 2.10 Reduction of 11-oxo-ETE and [13C20]-15-oxo-ETE to
11(S)-HETE and [13C20]-15(S)-HETE in Caco-2 cell line. Figure2.10(a)
and 2.10(b) show the basal level of 11-HETE and [13C20]-15(S)-HETE in Caco2 cell lysate, while 2.10(c) and 2.10(d) represent the formation of 11(S)HETE and [13C20]-15(S)-HETE after treating Caco-2 cell lysate with 100 nM
11-oxo-ETE and [13C20]-15(S)-HETE for 10 min at 37 °C. 11-HETE was
monitored as PFB derivative in negative mode by SRM m/z 319→167, while
[13C20]-15(S)-HETE was monitored by 339→233. The peak in 9(a) and (c) at
10.1 min is corresponding to 11(R)-HETE, while 11.8 min is 11(S)-HETE. The
retention time of [13C20]-15(R)-HETE is 11.4 min, while its (S) form is 15.0
min.

2.4.9 Effects of Eicosanoids on HUVEC Proliferation.
Proliferation by HUVECs was assessed by quantifying the BrdU incorporation
into the cells actively synthesizing new DNA. The BrdU assay was performed
using a quantitative colorimetric 96-well format ELISA as well as by
immunofluorescence microscopy for observing the morphological effects of
eicosanoids in HUVECs. For the BrdU ELISA, HUVECs (2000 cells/well) were
treated with different doses (0-100 M) of 11-oxo-ETE and 15d-PGJ2 for a
period of 24h. The cell numbers corresponding to each treatment dose were
computed and used to calculate cell proliferation (%) as compared to the
vehicle-treated controls.

11-Oxo-ETE (IC50 = 2.1 M) was equipotent with

15d-PGJ2 (IC50 = 2.3 M), a known potent inhibitor of endothelial cell
proliferation (Figure 2.11a). For the immunofluorescence analysis, HUVECs
(8000 cells/chamber) were treated with 2 M of either 11-oxo-ETE or 15dPGJ2 for 24 h.

BrdU incorporation was assessed by counting the BrdU-

positive cells as compared to the total number of cells counted in randomly
selected microscopic fields (10 fields/treatment).
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The photomicrographs

clearly show that treatment with 11-oxo-ETE as well as 15d-PGJ2 remarkably
reduced the total number of BrdU-positive cells (stained red) as compared to
vehicle-treated controls (Figure 2.11b).

Moreover, there was a distinct

change in the morphological appearance of the DAPI-stained (stained blue)
cells in the eicosanoid-treated slides that failed to incorporate BrdU (Figure
2.11b).
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Figure 2.11. Effect of eicosanoids on cell proliferation of HUVECs. (a)
For BrdU ELISA, HUVECs (2000 cells/well) were treated with various doses of
11-oxo-ETE and 15d-PGJ2 for a period of 24 h. Cell proliferation (means +
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S.E.M.) was assessed by measuring absorbance at 370 nm and converting it
to cell numbers using a standard curve and thereby used to construct the
IC50 plots.
All experiments were conducted three times in triplicate.
Representative data from one experiment conducted in triplicate are shown
as means ± S.E.M. (b) For immunofluorescence, HUVECs (8000/chamber)
were treated with 2 M of 15d-PGJ2 or 11-oxo-ETE for 24 h and then stained
for BrdU and counterstained with DAPI (cells stained blue). Photomicrographs
were taken at x200 magnification, and BrdU-positive (stained purple) cells
were counted in randomly selected microscopic fields (10/replicate) as
compared to the total number of cells in these fields. All experiments were
conducted in triplicate. Representative photomicrographs from one set of
replicates are shown.

2.5 DISCUSSION
15-PGDH catalyzes NAD+-mediated oxidation of the 15(S)-hydroxyl moiety
of PGs and other eicosanoids (Figure 2.1) (52, 58, 68). Previous studies had
established that 15-PGDH is also responsible for metabolizing the 15-LOXderived 15(S)-HETE in macrophages and monocytes to 15-oxo-ETE (68).
Surprisingly, it was found that 11(R)-HETE is also metabolized by 15-PGDH
to a novel eicosanoid, that was identified as 11-oxo-ETE (Figure 2.3).
Moreover, the catalytic activity of human 15-PGDH for oxidation of 11(R)HETE (Figure 2.3) was very similar to that observed for 15(S)-HETE. These
results were very surprising in view of the lack of a 15(S)-hydroxyl group on
11(R)-HETE as well as the incorrect 11(R)-stereochemistry. The structure of
11-oxo-ETE metabolite was established by chemically synthesizing authentic
11-oxo-ETE from racemic 11-HETE.

11-Oxo-ETE was formed in both LoVo

cell lysates (Figure 2.7a) and secreted from intact cells (Figure 2.8a);
whereas 11-oxo-ETE was not formed by HCA-7 cell lysates (Figure 2.7b) or

58

secreted from intact cells (Figure 2.8b). Since LoVo cells express COX-2 as
well as 15-PGDH, whereas HCA-7 cells express COX-2 but not 15-PGDH (52,
70, 71), these data convincingly prove that 11-oxo-ETE is an endogenous
product formed enzymatically by a combination of COX-2 and 15-PGDH.
11-oxo-ETE is isomeric with 15-oxo-ETE (Figure 2.2) and also has very
similar LC properties. Therefore, a reversed phase LC-SRM/MS method was
developed to separate the un-derivatized oxo-ETEs, and normal phase was
implemented to separate their PFB derivatives. This made it possible to
readily analyze the two oxo-ETEs. Endogenous eicosanoids formed by LoVo
and HCA-7 epithelial cells and cell lysates as well as those formed after the
addition of AA were analyzed as PFB derivatives by chiral LC-ECAPCI/MS (72,
73).

Representative

chromatograms

of

the

eicosanoids

produced

endogenously in the LoVo cell lysates are shown in Figure 2.6. Inhibition of
15-PGDH enzyme by CAY10397 significantly diminished the formation of
endogenous 11-oxo-ETE in LoVo cell lysates (Figure 2.7a). In addition, the
formation of 15-oxo-ETE as well as 13,14-dihydro-15-oxo-PGE2, the other
two 15-PGDH-dependent metabolites, were also significantly reduced in LoVo
cell lysates treated with CAY10397 (Figure 2.7a). In contrast, the three 15PGDH products, namely, 11-, 15-oxo-ETE and 13,14-dihydro-15-oxo-PGE2,
were undetectable in HCA-7 cells as these cells do not express any 15-PGDH
(52, 70). Instead, the corresponding precursors for these three metabolites
were observed in the lysates. Furthermore, treatment with CAY10397 had
no effect on levels of 11(R)-HETE, 15(S)-HETE or PGE2 (Figure 2.7b). Intact
LoVo cells also secreted 11-oxo-ETE, 15-oxo-ETE as well as 13,14-dihydro59

15-oxo-PGE2. However, the 11-oxo-ETE was cleared very rapidly (Figure
2.8a), suggesting that further metabolism was occurring.

Subsequently, it

was observed that 11-oxo-ETE underwent GST-mediated metabolism to 11OEG, similar to the formation of 15-OEG in RIES cells (Figure 2.9) (43).
Moreover, it was observed that 11-oxo-ETE and [13C20]-15-oxo-ETE could be
converted to 11(S)-HETE and [13C20]-15(S)-HETE in the Caco-2 cell line,
which does not express 15-PGDH. Therefore, a reductive pathway could be
responsible for the formation of endogenous 11(S)-HETE.
11-Oxo-ETE differs from 15d-PGJ2 in the lack of a C-8 to C-12 bond, in
having a cis-8,9- rather than cis-9,10-double bond, and a cis- rather than
trans-14,15-double bond (Figure 2.2). This suggested that 11-oxo-ETE might
be a more effective inhibitor of HUVEC proliferation than 15-oxo-ETE (68)
with a potency similar to that observed for 15d-PGJ2 (61). In fact, 11-oxoETE was six times more potent than 15-oxo-ETE (data not shown) and
equipotent with 15d-PGJ2 at inhibition of HUVEC proliferation (Figure 2.10).
Dose-response studies revealed that its IC50 was 2.1 M compared to an IC50
value of 2.3 M for 15d-PGJ2 (Figure 2.10a). Moreover, immunofluorescence
microscopy revealed that 11-oxo-ETE not only inhibited BrdU incorporation
into the HUVECs but it also caused a dramatic change in the shape and
morphology of these cells (Figure 2.10b). Although the total number of cells
counted in the eicosanoid-treated groups were quite similar to the vehicletreated group, the BrdU-negative cells were significantly distorted (Figure
2.10b). Typically, if the cells are undergoing death by apoptosis, they would
appear more compact and round.

However, 11-oxo-treated cells were
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elongated and stretched (Figure 2.10b), which could be indicative of
extensive cytoskeletal remodeling, cell cycle arrest and/or differentiation.
Interestingly, 11-oxo-ETE formation could not be detected in HUVEC lysate
that was incubated with 11(R)-HETE (data not shown). Finally, immunoblot
analysis of HUVEC cell lysate failed to detect COX-2 protein (data not shown).
Taken together, these data suggest a paracrine role for 11-oxo-ETE on
endothelial cell proliferation.
As noted above, inhibition of 15-PGDH resulted in significant decreases in
11-oxo-ETE formation in LoVo cells (Figure 2.7). 15-PGDH is down-regulated
in numerous cancers types (49, 52-56), which would cause a decrease in 11oxo-ETE biosynthesis by preventing the in vivo conversion of 11(R)-HETE to
11-oxo-ETE (Figure 2.1). This could be particularly devastating as COX-2
becomes up-regulated during tumorigenesis, which would result in elevated
PGE2 biosynthesis along with decreased 15-PGDH-mediated inactivation to
15-oxo-PGE2 (Figure 2.1). Ultimately, this would result in an increase in
PGE2-mediated pro-proliferative activity (48,57) without the counter effect of
anti-proliferative oxo-ETEs. Increased PGE2 activity can also arise through
down-regulation of the influx PG transporter - the organic anion transporter
polypeptide (OATP) 2A1 (Figure 2.1) (74,75).
There is some evidence that 11-oxo-ETE can activate nuclear PPAR.(76)
PPAR

is

a

ligand-dependent

transcription

factor

responsible

for

the

regulation of a number of cellular events ranging from lipid metabolism to
apoptosis.(77) 15d-PGJ2 is a PPAR agonist, which might account for its
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ability to inhibit endothelial cell proliferation (60,61). However, this effect is
only observed with pharmacological amounts of 15d-PGJ2 rather than
endogenous concentrations (69). Besides PPAR agonistic activity, 15d-PGJ2
is also known to be an inhibitor of NFB signaling, a pathway critical to cell
proliferation as well as tumorigenesis (78,79). In view of the ability of COX2/15-PGDH to rapidly metabolize AA to nM amounts of oxo-ETEs, together
with the structural similarity of oxo-ETEs and 15d-PGJ2 (Figure 2.2), it will be
important to determine which of these activities are shared by both classes
of

eicosanoids.

It

is

noteworthy

that

docosahexaenoic

acid

and

docosapentaenoic acid can be metabolized by the sequential action of COX-2
and dehydrogenises into oxo-eicosanoids that modulate the antioxidant
response (21). Similarly 5-LOX-drived 5(S)-HETE is metabolized by 5hydroxyeicosanoid dehydrogenase into the chemoattractant 5-oxo-ETE (80).
Therefore, the oxo-eicosanoids represent a family of oxidized lipids with
diverse biological activities.
In summary, these studies have revealed that down-regulation of 15-PGDH
inhibits the formation of the endogenous anti-proliferative eicosanoid, 11oxo-ETE. Therefore, 15-PGDH has two quite distinct properties; it can either
inactivate PGs or activate HETEs to oxo-ETEs that exert a paracrine effect on
endothelial cells (Figure 2.1). 11-Oxo-ETE, a member of the oxo-ETE family
(80-82), was observed previously as an endogenously-derived lipid in human
atherosclerotic plaques (83). However, the biosynthesis of 11-oxo-ETE and
its biological activity were not evaluated in that study. Furthermore, there
does not appear to be any subsequent report of its formation either, in vitro
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or in vivo. In fact 11-oxo-ETE is derived from COX-2/15-PGDH-mediated AA
metabolism and it inhibits endothelial cell proliferation with an IC50 that is
very similar to that of 15d-PGJ2.
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Chapter 3

Cyclooxygenase-2-mediated reactive
aldehyde formation

3.1 ABSTRACT
HNE and ONE are major products of lipid. These bifunctional electrophiles
have many biological effects, which is probably due in part to their high
reactivity with endogenous nucleophiles, such as glutathione, proteins and
DNA. HNE has a chiral center at C4. Some recent research has revealed that
the chirality of HNE is significant since its two enantiomers differ in their
ability to damage proteins and undergo detoxification. Thus, it is important to
study the formation of HNE with respect to chirality. In order to accomplish
this goal, HNE was analyzed as its GSH-adduct form, which allowed increased
detection sensitivity. It was found that in the presence of GSH, PGG2 and
15(S)-HPETE mainly produced 4(S)-HNE-GSH. In contrast 11(R)-HPETE
produced racemic HNE-GSH while 15(R)-HPETE produced 4(R)-HNE-GSH.
This new finding that HNE formed from different lipid hydroperoxides
possessing different chiral characteristics suggested a new decomposition
mechanism for lipid hydroperoxides. Interestingly, it was observed that 4(S)HNE-GSH

was

the

predominant

isomer

arising

from

incubations

of

recombinant COX-2 with AA in the presence of GSH. However, with aspirinmodified COX-2, 4(R)-HNE-GSH was the major product. This observation is
in keeping with the known activity of aspirin, which converts COX-2 into a
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15(R)-LOX

and

produces

mainly

15(R)-HPETE.

Human

colorectal

adenocarcinoma (LoVo) epithelial cells, which over-expressed COX-2, also
mainly generated 4(S)-HNE-GSH (86%) in the cell lysate when they were
treated with AA. This result together with the eicosanoid quantification assay
showed that in LoVo cells, HNE and ONE were formed mainly from PGG2 and
not from the HPETEs as has been previously thought. ONE formed on nuclear
membranes can covalently modify DNA due to its close proximity, resulting in
mutagenic DNA adducts, such as heptano-etheno-2’-deoxyguanosine (HdGuo).

3.2 INTRODUCTION
PGG2 (Figure 1.1) has been implicated in many inflammatory diseases, since
PGG2 is the precursor of pro-inflammatory prostaglandins. However, before
PGG2 is converted to PGH2, PGE2 and other PGs, it could also undergo
decomposition to malondialdehyde (MDA), together with HNE, and ONE have
been characterized as cytotoxic and genotoxic lipid peroxidation products
(32). MDA forms Schiff-base adducts with proteins or DNA bases, while HNE
and ONE form adducts through Michael addition (32). When MDA is at
physiological pH, it exists mainly in the enolate form, which has lower
reactivity compared to HNE and ONE. HNE formation has been implicated as
a

reactive

intermediate

in

many

diseases,

such

as

atherosclerosis,

Alzheimer’s disease, diabetes and Parkinson’s disease (84-86). HNE has one
chiral center and different strategies have been applied to study HNE
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enantiomers, including chiral LC-UV, LC-MS, NMR, fluorescence, as well as
anti-HNE antibody methods (87-91). The Uchida group has studied the
nature of HNE enantiomers selectively and differentially binding to proteins
(91, 92), while the Picklo group showed that HNE detoxification by GST or
AKR is also stereoselective (93, 94). Furthermore, the Brash group has
demonstrated that 4(S)-HNE is formed with high enantioselectivity from the
decomposition of 15(S)-HPETE (89). It was established that in LoVo cells,
PGs were the major COX-2 mediated arachidonic acid metabolites (95).
Therefore, this provided an excellent model system to examine the
mechanism of formation of COX-2-derived HNE (Figure 1.1) and ONE. This
would then make it possible to definitively identify the source of ONE-derived
DNA-adducts such as H-dGuo.
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Figure 3.1 Structures of PGE2, HNE-oxime, HNE-GSH-adducts and HdGuo.

Figure 3.2. The proposed mechanism of the transformation of PGG 2
into HNE and ONE. There might be an intermediate hydroperoxide, 12(S)HPTrE, which is formed together with MDA from PGG2 decomposition. The
hydrogen attached to C7 is abstracted, followed by the formation of a
carbon-centered radical at C7, and then the double bond between C8 and C9
relocates to C7 and C8, together with the relocation of C7 radical to C9
radical. A hydroperoxide radical is formed after an oxygen molecule radical to
C9 radical. A hydroperoxide radical is formed after an oxygen molecule
inserts to C9 position, followed by hock rearrangement and the formation of
4(S)-HPNE. The 4(S)-HPNE is then converted to 4(S)-HNE and ONE.

3.3 EXPERIMENTAL PROCEDURES
3.3.1 Chemicals and Reagents.
AA (peroxide-free), 11(R,S)-HETE, 15(R,S)-HETE, [2H8]-15(S)-HETE, [2H8]12(S)-HETE, 12(S)-HHT, PGE2, [2H4]-PGE2, PGF2α, [2H4]-PGF2α, [2H3]-4-HNE,
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PGG2, protease inhibitor cocktail (100X), recombinant ovine COX-1 and
human COX-2 were purchased from Cayman (Ann Harbor, MI). 2,3,4,5,6pentafluorobenzyl (PFB) bromide, Trizma-HCl, ethacrynic acid, hematin
porcine, hydroxylamine hydrochloride, L-glutathione, phenol, L-ascorbic acid,
zopolrestat, 2’-deoxyguanosine monohydrate and lipoxidase from Glycine
max (soybean) were purchased from Sigma-Aldrich (St. Louis, MO).
Rofecoxib was purchased from Sequoia Research Products (UK). Fetal bovine
serum (FBS) was from Gemini Bioproducts (West Sacramento, CA). F12K
medium, D-glucose, L-glutamine, penicillin, and streptomycin were supplied
by Invitrogen (Carlsbad, CA). LC-MS grade water, hexane, methanol,
isopropanol, acetonitrile and dichloromethane were obtained from Fisher
Scientific (Pittsburgh, PA). Gases were supplied by The Linde Group (Munich,
Germany).
3.3.2 Cell Culture.
LoVo

cells

(ATCC,

Manassas,

VA)

were

cultured

in

F12K

medium

supplemented with 10% FBS, 2 mM L-glutamine, 100,000 units/l penicillin
and 100 mg/l streptomycin.
3.3.3 MS conditions.
A triple stage quadrupole (TSQ Quantum) mass spectrometer (Thermo
Electron, San Jose, CA) equipped with an APCI source was used for the
quantitative lipidomics analyses. Targeted chiral LC-ECAPCI/SRM/MS analysis
was conducted using PFB derivatives of 7 lipids and 4 heavy isotope analog
internal standards. For the lipidomics profile, the instrument was operated in
68

the negative ion mode, and unit resolution was maintained for both precursor
and fragment ions. Operating conditions for the TSQ Quantum were:
vaporizer temperature at 450°C; heated capillary temperature at 250 °C with
the corona discharge needle set at 30 µA; nitrogen as sheath (25 psi) and
auxiliary (5 arbitrary units) gas. Collision-induced dissociation (CID) was
performed using argon as the collision gas at 1.5 mtorr in the RF-only
quadrupole. The following SRM transitions were used: 11(R)-HETE-PFB, m/z
319 → 167 (CE, 16 eV), 15-HETE-PFB, m/z 327 → 226 (CE, 13 eV), 12(S)HHT-PFB, m/z 279 → 217 (CE, 18 eV), [2H8]-15(S)-HETE-PFB, m/z 327 →
226 (CE, 13 eV), [2H8]-12(S)-HETE-PFB, m/z 327 → 184(CE, 14 eV), PGE2PFB, m/z 351 → 271 (CE, 18 eV), [2H4]-PGE2-PFB, m/z 355 → 275 (CE, 18
eV), PGD2-PFB, m/z 351 → 271 (CE, 18 eV), [2H4]-PGD2-PFB, m/z 355 → 275
(CE, 18 eV), PGF2α-PFB, m/z 353→ 193 (CE, 25 eV), [2H4]- PGF2α-PFB, m/z
357→ 197(CE, 25 eV).
For oxime derivatives analysis, the Finnigan LTQ mass spectrometer (Thermo
Electron, San Jose, CA) was used in the positive ion mode with an
electrospray ionization (ESI) source. The operating conditions were: spray
voltage at 4 kV; capillary temperature at 250 °C; capillary voltage at 35 V;
nitrogen as sheath (40 psi) and auxiliary (20 arbitrary units) gas. CID was
performed using helium as the collision gas in the ion trap. The following
SRM transition (m/z 188 → 154) was monitored for HPNE-oxime (normalized
CE, 25 %), and SRM transition (m/z 172 → 99) was monitored for HNEoxime (normalized CE, 25%).
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For GSH adduct analysis, the TSQ Quantum was operated in the positive ion
mode with an ESI source. The operating conditions were: spray voltage at 4
kV; capillary temperature at 350°C; nitrogen as sheath (35 psi) and auxiliary
(13 arbitrary units) gas. CID was performed using argon as the collision gas
at 1.5 mtorr in the Rf-only quadrupole. The following SRM transition (m/z
464 → 308) was monitored for HNE-GSH (CE, 14 eV).
For H-εdGuo analysis, the TSQ Quantum was operated in the positive ion
mode with an ESI source. The operating conditions were: spray voltage at 4
kV; capillary temperature at 320°C; nitrogen as sheath (25 psi) and auxiliary
(10 arbitrary units) gas. CID was performed using argon as the collision gas
at 1.5 mtorr in the Rf-only quadrupole. The following SRM transition (m/z
404 → 288) was monitored for H-εdGuo (CE, 18 eV).
3.3.4 LC methods.
LC separations were conducted using a Waters Alliance 2690 HPLC system
(Waters Corp., Milford, MA, USA). A Chiralpak AD-H column (250 × 4.6 mm
inner diameter, 5 µm; Daicel Chemical Industries, Ltd., Tokyo, Japan) was
employed for normal phase separation (flow-rate 1 ml/min) of PFBderivatives of eicosanoids. Gradient 1 was used for separating PFBderivatives of HETEs and PGE2. For gradient 1, solvent A was hexane, and
solvent B was methanol/isopropanol (1:1; v/v). Gradient 1 was as follows: 2%
B at 0 min, 2% B at 3 min, 3.6% B at 11 min, 8% B at 15 min, 8% B at 27
min, 50% B at 30 min, 50% at 35 min, and 2% B at 37 min. Separations
were performed at 30 °C using a linear gradient.
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A Chiralpak AD-RH column (150 × 4.6 mm inner diameter, 5 µm; Daicel
Chemical Industries, Ltd., Tokyo, Japan) on Waters Alliance 2690 HPLC was
used for reverse phase (isocratic method 1, flow-rate 0.5 ml/min) separation
of the HNE and HPNE oxime derivatives. The mobile phase for isocratic
separations was methanol/water (85:15; v/v) with 0.1% formic acid. 4(R,S)HNE was separated on the same column connected to Hitachi L-6200 LC with
mobile phase of methanol/water (85:15, v/v), and the UV absorbance was
set at 236 nm with L-4000 UV detector (isocratic method 2). For 4(R,S)HPNE, the mobile phase was methanol/water (78:12, v/v, isocratic method
3). Separations were performed at room temperature.
Chemically synthesized Me-15(S)-HPETE was purified by normal-phase
(isocratic method 4) preparative LC (Ultrasphere™ 250 × 10 mm, inner
diameter, 5 µm; Beckman) using Hitachi LC system by monitoring the UV
absorbance at 236 nm. The mobile phase for isocratic method 2 was
hexane/isopropanol (197:3, v/v) containing 0.1% acetic acid.
Chemically synthesized Me-15(R)-HPETE was purified by normal-phase
(isocratic method 5) LC (Chiralpak AD-H 250 × 4.6 mm, inner diameter, 5
µm) using Hitachi LC system by monitoring the UV absorbance at 236 nm.
The mobile phase for isocratic method 4 (flow-rate 1 ml/min) was
hexane/ethanol (100:2; v/v). The separation was performed at ambient
temperature using a linear gradient.
GSH adducts were separated by reversed phase using gradient 2 on Waters
Alliance 2690 HPLC system. The separation employed a Phenomenex Synergi
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Hydro-RP column (150 × 4.6 mm inner diameters, 5 µm). Solvent A was 0.1%
aqueous formic acid, and solvent B was methanol/acetonitrile/formic acid
(50:50:0.1; v/v). Gradient 2 was as follows: 2% B at 0 min, 12% B at 14
min, 30% B at 20 min, 42% B at 21 min, 65% B at 27 min, 80% B at 29 min,
90% B at 33 min, 90% B at 34 min, 2% B at 35 min. The flow rate was 0.4
ml/min.

The separation was performed at ambient temperature using a

linear gradient.
H-dGuo was separated by reversed phase using gradient 3 on Waters
Alliance 2690 HPLC system. The column used was Phenomenex Kinetex C18
(100 × 2.1 mm inner diameters, 2.6 µm). Solvent A was 0.1 % aqueous
formic acid, and solvent B was acetonitrile/formic acid (100:0.1; v/v).
Gradient 3 was as follows: 10% B at 0 min, 10% B at 3 min, 30% B at 3.5
min, 90% B at 15 min, 90%B at 22 min, 10% B at 23 min. The flow rate was
0.2 ml/min. The separation was performed at ambient temperature using a
linear gradient.
3.3.5 Chirality of HNE-GSH adduct formed from eicosanoids.
HPETEs or PGG2 (1.7 µM) were incubated at 37 oC with hematin (100 nM) and
GSH (4 mM) in 200 µl 100 mM Tris-Cl (pH 7.9) for 30 min, and reaction
mixtures were loaded onto SPE column (oasis HLB, 30 mg) pre-conditioned
with methanol and then 0.1% formic acid. The column was washed with 1 ml
water and eluted with 250 µl methanol, and then 20 µl was analyzed by
reverse phase LC-ESI/MS using gradient 2, as described above. Each sample
was prepared in triplicate.
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3.3.6 Formation of the ONE dGuo adduct (H-dGuo) from PGG2.
PGG2 or 15(S)-HPETE (15 µM) in 200 µl Chelex-treated 100 mM MOPS
buffer(pH 7.2), containing 150 mM NaCl was incubated with 100 µM
NH4Fe(SO4)2 and 100 µM dGuo at 37 °C for 24 hrs. Ethyl acetate (2 × 800 µl)
was added to extract products. Organic layer was evaporated and dissolved
to 100 µl MeOH/H2O (1:9; v/v). 20 µl of each sample was injected to LCESI/MS (gradient 3).
3.3.7 Kinetic study of AA metabolism by COX.
6.7 nM recombinant ovine COX-1 or 14 nM recombinant human COX-2 was
pre-incubated with cofactor hematin (100 nM), phenol (1 mM) and GSH (4
mM) in 100 mM Tris-Cl (pH 7.9) for 60 sec at 37oC before adding various
concentrations of AA (0, 2.5 M, 5 M, 10 M, 20 M and 50 M). Each total
reaction volume was 200 l.

In separate experiments, the formation of

eicosanoids was found to be linear for the first 45 sec. After 30 sec
incubation, the enzymatic reaction was quenched by adding 400 l of ice-cold
methanol and strong vortex. 20 µl 10% aqueous acetic acid was added to
adjust pH to 3-4, together with 20 µl internal standards mixture (50 pg/ µl
[2H8]-15(S)-HETE,

[2H8]-12(S)-HETE,

[2H4]-PGE2

and

[2H4]-PGF2α).

The

control samples were prepared by incubating same concentrations of AA with
denatured COX for 30 sec in the same buffer as above. Eicosanoids were
extracted with 1.2 ml of dichloromethane/methanol (8:1; v/v). The lower
organic

layer

was

then

evaporated

to

dryness

under

nitrogen

and

reconstituted in acetonitrile (100 l). PFB derivatives were synthesized as
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described above and analyzed by normal phase LC-ECAPCI/MS. Here,
hematin stock solution (1mM in 0.1N NaOH) was prepared weekly, while
phenol and GSH solutions were freshly prepared.
Eicosanoids were quantified by interpolation from a standard curve prepared
with 15-HETE, 11-HETE, 12(S)-HHT, PGE2 and PGF2α using [2H8]-15(S)-HETE,
[2H8]-12(S)-HETE, [2H4]-PGE2, and [2H4]-PGF2α as the internal standard.
Samples were prepared in duplicate.
3.3.8 Eicosanoids profile of AA metabolism by COX.
Recombinant ovine COX-1 or human COX-2 (25 nM) was incubated with 5 µM
AA in 200 µl 100 mM Tris-Cl buffer (pH 7.9), containing 1 µM hematin, 1 mM
phenol and 4 mM GSH. The incubation was kept at 37 °C for 30 min, and
then the reaction mixtures were added with internal standards (50 pg/ µl
[2H8]-15(S)-HETE, [2H4]-PGE2 and [2H4]-PGF2α. The products were extracted
with diethyl ether (2×600 µl) at pH 3-4. The organic layer was evaporated in
N2 flow and PFB derivatives were made before analysis by LC-ECAPCI /MS.
3.3.9 Standard curves for eicosanoid quantification.
To quantify eicosanoids from COX mediated AA metabolism, Eppendorf tubes
containing 0.2 ml 100 mM Tris-Cl (pH 7.9) were spiked with lipid standards,
together with internal standards for ([2H8]-15(S)-HETE , [2H8]-12(S)-HETE,
[2H4]-PGE2 and [2H4]-PGF2α, 1 ng each). The extraction and PFB derivatization
methods are the same as mentioned above. Each sample was prepared in
duplicate.
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3.3.10

Chirality

of

HNE-GSH

formed

from

COX

mediated

AA

metabolism.
25 nM COX-1 or COX-2 were incubated with 5 µM AA in 100 mM Tris-Cl (pH
7.9) in the presence of hematin (1 µM), phenol (1mM), and GSH (4mM). The
total volume reaction mixture volume was 200 µl. Here, arachidonic acid (10
µM) was pre-incubated with Girard T reagent (30 mM) in Tris-Cl buffer with 5%
acetic acid for 20 min at R.T. Then 2 volume of hexane was added to extract
arachidonic acid. Hexane layer was transfer to a separate tube, and
evaporated in N2 flow, and then re-dissolved to Tris-Cl buffer before adding
to reaction mixture. After 30 min, the reaction mixtures were then acidified
with 10% aqueous acetic acid (10 µl) to pH 3-4, followed by addition of the
internal standard mix,

[2H3]-HNE-GSH (5 pg/µl, 20 µl). Samples were

centrifuged at 13500 rpm for 2 min. The supernatant was purified by SPE
cartridge and analyzed by LC-ESI/MS, as described above. Samples were
prepared in triplicate. Here, [2H3]-HNE-GSH was prepared by incubating 4(S)-HNE and 4-(R)-HNE with GSH, respectively. 4(S)-HNE and 4-(R)-HNE
were as described previously (89), using isocratic method 2.
3.3.11 Standard curves for HNE-GSH quantification.
To quantify HNE-GSH adduct from COX-mediated AA metabolism, standard
HNE (0.01, 0.1,0.5,2 and 10 ng) was incubated with GSH (4 mM) at 37 ºC
for 30 min, and then [2H3]-HNE-GSH (5 pg/µl, 20 µl) was added to reaction
mixtures. The reaction mixtures were purified by SPE cartridge and analyzed
by LC-ESI/MS as previously described.
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3.3.12 Chirality of HNE-GSH formed from LoVo cell lysate.
LoVo cells were grown to 90% confluence, washed with phosphate-buffered
saline (PBS) buffer (2×10ml), and then gently scraped in 400 µl of lysis
buffer containing 100 mM Tris-HCl (pH 7.9), protease inhibitor (diluted from
100X), GSH (4 mM), GST inhibitor ethacrynic acid (20 µM) and AKR inhibitor
zopolrestat (50 nM). Cell suspension was transferred to 2 ml Eppendorf tubes,
and sonicated for 60 seconds on ice (power 5). Cell lysate was then
incubated for 15 min at 37°C. The pH was then adjusted to 3 to 4 with 10%
aqueous acetic acid (10 µl) followed by addition of the internal standard mix,
[2H3]-HNE-GSH (5 pg/µl, 20 µl). Samples were centrifuged at 13500 rpm for
2 min, and the supernatant was purified by SPE cartridge. The cartridge was
eluted with 250 µl methanol, and 40 µl was analyzed by LC-ESI/MS. For the
control samples, LoVo cells were pretreated with rofecoxib (50 M) in F-12K
medium at 37°C for 2 hrs to inhibit COX-2 activity, and then cell lysate was
prepared as described above. To quantify eicosanoids formation under this
condition, a separate set of samples were prepared, and the lipid extraction
and PFB derivatization methods described previously were used.
3.3.13 Methylation of 15(S)-HPETE.
Ethereal diazomethane (CH2N2) was freshly prepared by reacting N-methylN-nitroso-p-toluensulfonamide

with

sodium

hydroxide,

employing

a

diazomethane generator from Wheaton (Millville, NJ). The manufacturer’s
procedures were followed, and the product was confirmed by both LC-MS and
NMR.
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3.3.14

Chemical synthesis and purification of 15(R)-HPETE methyl

ester.
15(R)-HPETE methyl ester was synthesized according to Corey’s method
(104, 105). Racemic 15-HPETE methyl ester was prepared by converting
15(S)-HETE methyl ester to the mesylate derivative, which was then treated
with hydrogen peroxide in ether at -110 °C. 15(R)-HPETE methyl ester was
isolated by normal phase-HPLC using isocratic method 5.
3.3.15 Separation and hydroxylamine derivatization of 4(S)-HPNE.
4(R,S)-HPNE from Cayman was separated by Chiralpak AD-RH column, as
described previously (isocratic method 3). The first peak of the two
enantiomers was collected and evaporated in N2 flow, and then it was
dissolved into 200 µl Chelex-treated MOPS buffer (100 mM, pH 7.2),
containing 150 mM NaCl, followed by the addition of 1 mg hydroxylamine
hydrochloride. The mixture was incubated at 37 ºC for 1 h before extraction
with ethyl acetate (2 × 800 l). The organic layer was evaporated in N2 flow,
and then dissolved to 100 l MeOH. 10 l was analyzed by LC-LTQ/MS, as
described above. The rest of the solution was added with 0.4 mg SnCl2 and
stayed at room temperature for 30 min. Water (900 l) was added and then
3 ml ethyl acetate, and the mixture was centrifuged at 3000 rpm for 5 min.
Then the ethyl acetate was evaporated and dissolved to 100 l MeOH/water
(85:15; v/v), and 10 µl was injected to LC-ESI/SRM/MS (isocratic method 1).
4(S)-HNE isolated from 4(R,S)-HNE (89) was also converted to the oxime
derivative under the same condition as used for HPNE. By comparison of
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4(S)-HNE oxime peak from standard 4(S)-HNE with that obtained from the
reduction of HPNE-oxime, it was possible to conclude that the first peak,
which eluted from the AD-RH column was 4(S)-HPNE.
3.3.16 Conversion of 4(S)-HPNE-oxime to 4(S)-HNE-oxime in the
presence of Vit C.
4(S)-HPNE-oxime prepared as described above was separated with an AD-RH
column using isocratic method 1. The two isomer peaks were collected
separately, and then incubated 200 µl Chelex-treated MOPS buffer (100 mM,
pH 7.2), containing 150 mM NaCl and 1 mM Vit C, 37 ºC for 30 min. A similar
ethyl acetate extraction workup was applied to purify the products. The
samples were analyzed with the same LC-MS method as 4(S)-HNE-oxime.

3.4 RESULTS
3.4.1 Chirality of HNE-GSH formed from eicosanoids.
HNE was converted to its GSH-adduct in order to increase the sensitivity of
detection.

GSH also introduced new chiral centers, so the GSH-adduct

diastereomer formed from 4(S)-HNE and the one formed from 4(R)-HNE
could be readily separated with a non-chiral column. PGG2, 11(R)-HPETE,
15(S)-HPETE, and 15(R)-HPETE-Me (1.7 µM) were incubated with hematin
and GSH, resulting in the formation of different HNE-GSH diastereomers that
could be readily analyzed. A representative chromatogram (Figure 3.3)
reveals the separation of R-HNE-GSH (retention time 24.4 and 25.8 min) and
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S-HNE-GSH (retention time 24.9 min). 11(R)-HPETE gave racemic HNE-GSH.
15(S)-HPETE gave (S)-HNE-GSH, while 15(R)-HPETE-Me gave (R)-HNE-GSH.
PGG2 only gave (S)-HNE-GSH.

Figure 3.3. The chirality of HNE formed from eicosanoids. Figure (a),
(b), (c) (d) show the chromatography of HNE-GSH formed from 15(S)-HPETE,
15(R)-HPETE methyl ester, 11(R)-HPETE and PGG2, respectively. (e) is the
chromatography of 4(R,S) HNE and GSH adduct standard. HNE-GSH is
separated by reverse phase LC, and monitored by SRM transition m/z 464 to
308. The middle peak is 4(S)-HNE and GSH adduct. There are two peaks (the
first and the third) corresponding to GSH adduct with 4(R)-HNE. This is
because there are multiple chiral centers in HNE-GSH adducts.

3.4.2 Formation of H-εdGuo from PGG2.
PGG2 was incubated with dGuo in the absence or presence of Fe(II). PGG2
decomposed to ONE in the presence of Fe(II) and ONE was trapped by dGuo
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to form H-εdGuo. After 24 h incubation, the product was extracted with ethyl
acetate. The organic layer was evaporated and dissolved into starting mobile
phase. Samples were analyzed in LC-ESI/MS. The retention time of H-εdGuo
is 14.7 min, as shown in Figure 3.4.

Figure 3.4. The formation of H-dGuo from PGG2 and 15(S)-HPETE.
Samples were prepared from 15 µM PGG2 or 15(S)-HPETE in Chelex-treated
100mM MOPS buffer, containing 150 mM NaCl buffer (pH 7.2) in the
presence of 100 µM dGuo and in the presence or absence of 100 µM Fe(II) at
37 °C for 24 hr. Figure (a) and (b) show the H-dGuo formation from PGG2 in
the absence and presence of FeII, respectively. Figure (c) and (d) show the
H-dGuo formation from 15(S)-HPETE in the absence and presence of Fe,
respectively. Reverse phase LC coupled with SRM transition m/z 404 to 288
(collision energy 18 eV) was used to detect H-dGuo.
3.4.3 Kinetic study of AA metabolism by COXs.
Various concentrations of AA were incubated with recombinant ovine COX-1
and human COX-2 at 37 °C. A Michaelis-Menten kinetic analysis of
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eicosanoids formation revealed that the Vmax values for conversion of AA to
PGE2, 11(R)-HETE, 15(S)-HETE, and 15(R)-HETE by COX-1 are 25.16, 13.86,
13.83, and 3.856 pmol/min, respectively, while Km values are 3.768, 9.434,
19.76, and 8.334 µM, respectively, and the corresponding kcat values are
18.78, 10.34, 10.32, and 2.878 min-1, respectively (Figure 3.5, Table 3.1).

Table 3.1. The Km, Vmax, kcat and kcat/Km values of COX substrate AA
with the respect of different products.
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Figure 3.5. The saturation curves for recombinant ovine COX-1 and
human COX-2 with AA as the substrate. All of the samples were prepared
in duplicate (means ± S.E.M.)

3.4.4 Eicosanoid profile of AA metabolism by COX.
Recombinant ovine COX-1 or human COX-2 (25 nM) was incubated with 5 µM
AA in 200 µl 100 mM Tris-Cl buffer (pH 7.9), containing 1 µM hematin, 1 mM
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phenol and 4 mM GSH. The incubation was kept at 37 °C for 30 min, and
then the reaction mixtures were added with internal standards (50 pg/ µl
[2H8]-15(S)-HETE, [2H4]-PGE2 and [2H4]-PGF2α). The products were extracted
with diethyl ether (2 × 600 µl) at pH 3-4. The organic layer was evaporated
in N2 flow and PFB derivatives were made for LC-ECAPCI /MS analysis. The
results are shown in Figure 3.6. If PGE2, PGF2 and 12-HHT are used to
reflect the original PGG2 level, and15-HPETE and 11-HPETE to reflect the LOX
activity, then the PG pathway comprises > 88 % of the total COX-1
metabolites, and > 86 % for the COX-2 enzyme metabolites. The eicosanoids
formation from LoVo cell lysate were extracted and quantified following a
similar procedure. Figure 3.9 shows the products profiles from LoVo cell
lysate.

The

product

distribution

was

similar

to

that

obtained

from

recombinant COX-2. PG metabolites comprised > 82 % of the overall
eicosanoids, which indicates the initially formed PGG2 was the major COX-2derived metabolite.
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Figure 3.6. Eicosanoids formed from recombinant ovine COX-1 and
human COX-2. Data is performed in triplicate (means ± S.E.M.)

3.4.5

Chirality

of

HNE-GSH

formed

from

COX-mediated

AA

metabolism.
The HNE-GSH-adducts from 25 nM COX-1 or COX-2 incubation with 5 µM AA
were purified by SPE and then analyzed by LC-ESI/SRM/MS. A representative
chromatogram (Figure 3.7) reveals the separation of R-HNE-GSH (retention
time 24.4 and 25.8 min) and S-HNE-GSH (retention time 24.9 min). A
summary of the R, S percentage of HNE from different precursors is shown in
Table 3.2.
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Figure 3.7. Chirality character of HNE-GSH formed from COX
mediated AA metabolism Figure (a) shows HNE-GSH formed from COX-1
mediated AA metabolism, while HNE-GSH in Figure (b) comes from COX-2.
[2H3]-HNE-GSH in Figure (c) is racemic internal standard, which is monitored
by SRM transition m/z 467 to 308.

Substrates

4(R)-HNE(%)

4(S)-HNE(%)

11(R)-HPETE

52.0

48.0

15(S)-HPETE

7.0

93.0

15(R)-HPETE

94.0

6.0

COX-1 + AA

6.3

93.7

COX-2 + AA

8.5

91.5

PGG2

11.0

89.0
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Table 3.2 The chirality of HNE-GSH-adducts formed from different
hydroperoxides and COX-mediated AA metabolism

3.4.6 Chirality of HNE-GSH-adducts formed from LoVo cell lysate.
LoVo cells are known to express COX-2. This was confirmed by Western blot
analysis (data not shown).

LoVo cell lysates were incubated with 100 mM

Tris-Cl (pH 7.9), protease inhibitor, GSH (4 mM), GST inhibitor ethacrynic
acid (20 µM) AKR inhibitor zopolrestat (50 nM). [2H3]-HNE (5 nM) or AA (20
µM) was added and incubation was kept for 15 min. Inhibition of GST
abolished the effect of GST on enantioselective HNE-GSH-adduct formation.
The AKR1B inhibitor stabilized HNE-GSH.(23) Racemic [2H3]-HNE was added
to the lysate mixture, and racemic [2H3]-HNE-GSH was obtained (Figure
3.8c), which indicated that under this condition, the chirality of HNE-GSH
from LoVo cell lysate supplemented with AA would represent the chirality of
HNE formed from LoVo cell lysate (Figure 3.8b). Mainly, the S-HNE-GSHadduct was detected, which was consistent with the chiral analysis of
eicosanoids from LoVo cell lysates (Figure 3.9). Pre-treatment of rofecoxib
inhibited > 90% of PGE2 formation, so rofecoxib-treated LoVo cell lysate was
used to provide a control sample.
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Figure 3.8. The formation of 4(S)-HNE and GSH adduct from LoVo cell
lysate. Figure (a) displays HNE-GSH adduct from rofecoxib-treated LoVo cell
lysate, which is used to represent the basal level of HNE-GSH adduct. Figure
(b) shows HNE-GSH formed from LoVo cell lysate in the presence of
ethacrynic acid, zopolrestat, and GSH Figure (c) is the formation of [2H3]HNE-GSH after adding 250 pg [2H3]-HNE to LoVo cell lysate. All of these
experiments were done in triplicate, and this Figure reflects one of the
triplicates.
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Figure 3.9. Eicosanoids formed from LoVo cell lysate in the presence
of ethacrynic acid, ispolrestat, and GSH. All of the samples were
prepared in triplicate. As shown above, PGE2 was the major metabolite. 50
µM rofecoxib almost abolished the formation of eicosanoids from COX-2. All
of these experiments were performed in triplicate (means ± S.E.M.).

3.4.7 Separation and oxime derivatization of 4(R,S)-HNE and 4(R,S)HPNE
Both HNE and HPNE enantiomers could be separated on the same column,
although the separation of 4(R,S)-HNE was more efficient(see Figure 3.10). A
previous study had established that under these LC conditions, 4(S)-HNE is
eluted first (7.6 min) followed by 4(R)-HNE. In order to confirm the chirality
of the two HPNE enantiomers, the first eluting peak was collected and
reacted with hydroxylamine in 200 l 100 mM MOPS buffer with 150 mM
NaCl, pH7.2. The resulting oxime was extracted with ethyl acetate (800 l,
twice), and the organic layer was evaporated under N2. The HPNE-oxime was
then re-dissolved into 100 l methanol and 10 l was then analyzed by LC88

MS on the LTQ instrument. It was also was reduced to HNE-oxime by adding
SnCl2, and the mixture was incubated at room temperature for 30 min. The
product was again extracted with ethyl acetate. HNE-oxime formed from
HPNE-oxime reduction was analyzed by the same LC-MS method. Figure 3.10
shows that the first peak (15.2 min) collected from 4(R,S)-HPNE was reduced
to 4(S)-HNE only. The SnCl2 reduction did not change the chirality of
hydroperoxy group, so the 15.2 min peak corresponded to 4(S)-HPNE, while
the 16.2 min peak was 4(S)-HPNE.

4(S)-HNE

4(R)HNE

4(S)-HPNE
4(S)-HPNE
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Figure 3.10. Chiral LC separation of 4(R,S)-HPNE and 4(R,S)-HNE and
Chiral LC-MS analysis of their corresponding oxime derivatives.

Based on the data shown in Figure 3.10, the first peak eluted from AD-RH
column using 78% MeOH/water as the mobile phase corresponded to 4(S)HPNE. In the presence of Vit C, the 4(S)-HPNE could be converted to 4(S)HNE without changing the chiral center at C4. Thus, monitoring the chirality
of HNE would reflect the chiral character of HPNE.
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Figure 3.11 The conversion of 4(S)-HPNE-oxime to 4(S)-HNE-oxime
in the presence of Vit C. Figure (a) shows 4(S)-HPNE-oxime (syn- and
anti-isomers). Figure (b) is 4(S)-HNE-oxime isomer1 formed from 4(S)HPNE-oxime isomer1, while (c) is 4(S)-HNE-oxime isomer 2 formed from
4(S)-HPNE-oxime isomer2. Figure (d) shows the two isomers from standard
4(S)-HNE-oxime. The 4(R,S)-HPNE and 4(R,S)-HNE enantiomers are
separated by chiral AD-RH column. HPNE-oxime is monitored by SRM
transition m/z 188 to 154 at collision energy 25%, while HNE-oxime was
monitored by the SRM transition m/z 172 to 99 at the same collision energy.

3.4.8

Chemical synthesis and purification of 15(R)-HPETE methyl

ester.
The synthesis of 15(R)-HPETE methyl ester was achieved by converting
15(S)-HETE methyl ester to racemic 15-HETE methyl ester. 15(S)-HPETE was
prepared by oxidation of arachidonic acid from LO, and then methylated by
CH2N2. The reduction of the hydroperoxy group at C15 to alcohol was via
NaBH4 reduction. Acidic and basic hydrolysis of the methyl ester were
attempted to convert the methyl ester back to acid. However, the yield was
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extremely low due to the relative instability of 15-HPETE. A chiral AD-RH
column was applied to separate 15(R,S)-HPETE methyl ester as shown in
Figure 3.12.In the left LC-UV chromatogram, the peak at 17.2 min
corresponds to the S form of 15-HPETE-Me, while the peak at 18.2 min
corresponds to the R form. Figure 3.12(a) shows LC-ESI/MS data of racemic
15-HPETE methyl ester, while 3.12(b) shows 15(S)-HPETE-Me only, so the
peak at 10.6 min is 15(R)-HPETE-Me.

Figure 3.12, LC-UV purification and LC-MS confirmation of 15-HPETE
methyl ester. The reaction mixture was purified by Chiralpak AD-H column
with mobile phase of hexane/ethanol (100:2), and UV absorption at 236 nm
was monitored. Figure (a) and (b) are 15-HPETE-Me samples analyzed by
Chiralpak AD-RH column coupled with LTQ-ESI/MS. The LC-MS conditions are
shown in the experimental procedures section.
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3.5 DISCUSSION
HNE and ONE can be generated from linoleic acid and AA autoxidation in
vitro. However, in cells the redox potential is strictly regulated, which means
the free radical induced non-enzymatic autoxidation is very limited and the
corresponding autoxidation products are at low levels. In contrast, when
COXs and LOXs are present, linoleic acid or AA can be efficiently converted
stereoselectively into lipid hydroperoxides in inflammatory cells and in many
cancer tissues. The major product of COX-2 mediated AA oxidation is PGG2.
From analysis of HNE-GSH adduct generated from different eicosanoids, it
was shown that PGG2 could be converted into 4(S)-HNE; whereas, 11(R)HPETE, which is the major acyclic lipid hydroperoxide, generated racemic
4(R,S)-HNE. Furthermore, 15(S)-HPETE, a major product of the 15-LOX/AA
pathway, was converted into 4(S)-HNE, while 15(R)-HPETE, the major
product

of

aspirin-treated

COX-2,

was

converted

into

4(R)-HNE.

Characterization of the different eicosanoid-derived HNE enantiomers made it
possible to evaluate the individual contributions of these eicosanoid precursor
and their related pathways to formation of the reactive aldehydes HNE and
ONE. Interestingly, 4(S)-HNE was the major form of HNE formed from either
recombinant COX-mediated AA oxidation in the presence of hematin as well
as from COX-2 expressed LoVo cell lysate. This result indicates that PGG2
contributes is the major contributor to the formation of HNE. This means that
COX-derived ONE, which shares the same precursor as HNE, also arises from
PGG2. This new finding implies that ONE-mediated DNA damage also arises
from PGG2 rather than from HPETEs as had been assumed previously (67).
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The fact that PGG2 is mainly converted into 4(S)-HNE suggests a novel
decomposition mechanism. It is proposed that the 12-HPTrE formed when
PGG2 is converted to MDA forms a dihydroperoxide similar to that proposed
for 5(S)-HPETE (36), which subsequently decomposes to 4(S)-HPNE via a
Hock rearrangement. Furthermore, it further highlights the need for
adequate intracellular reducing equivalents to convert PGG2 into PGH2 and so
prevent the formation of MDA, HPNE, HNE, and ONE.
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Chapter 4
Newly identified OUDE as the 15-HPETE and 11(R)HPETE decomposition aldehyde

4.1 ABSTRACT
. HPNE and HPNE-derived HNE and ONE have been characterized previously.
However, OUDE, which retains a carboxylic acid group from HPETEs has not
been identified previously. The formation of OUDE from lipid hydroperoxide
decomposition

was

shown

to

occur

by

comparing

LC-MS

and

NMR

information to an authentic standard prepared by organic synthesis. Chiral
LC-MS analysis of oxime derivatives coupled with the use of [13C]-analogs
was employed in order to provide insight into the mechanism of formation of
OUDE. An OUDE isomer, which was formed by C8-C9 double bond
translocation to C9-C10 was also identified. This isomer possesses a reactive
,unsaturated aldehyde analogous to HNE. It was found that there are two
distinct pathways for 11(R)-HPETE and 15-HPETE to form OUDE and HPNE,
based on the different chirality of HPNE generated from these lipid
hydroperoxides. The findings of carboxylic acid containing aldehydes could be
highly significant, considering that they could be generated on esterified
lipids and disrupt the lipid membrane. This is different from HPNE, which
cannot form an ester bond to membrane lipids. Thus, HPNE or HNE could
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play quite different roles in regulating biological processes when compared to
the corresponding carboxylate-containing OUDE isomers.

4.2 INTRODUCTION
15-HPETE and 11-HPETE are generated either from autoxidation of AA as
racemic mixtures, or stereoselectively from enzymatic pathways. COX-2
converts free AA into 15(S)-HPETE and 11(R)-HPETE, while 15-LOX converts
free AA or esterified AA into free 15(S)-HPETE or esterified 15(S)-HPETE
(109). Both non-enzymatic pathways and enzymatic pathways are enhanced
in cells under oxidative stress such as during inflammation and cancer. It has
been known for many years that AA oxidation can generate aldehydes
(110,111). However, previous research has focused primarily on AA-derived
aldehydic products, which lack the -carboxylate terminus.. Thus, HNE and
ONE have been widely studied with regards to their mechanism of formation
(32,96) and their biological effects (97, 101-103, 107-108). However,
carboxylate containing aldehydes have attracted much less attention with
respect to either their identification or their biological roles.
A number of research groups have studied the oxidized phospholipid
products (OxPLs) that are present on the surface of LDL or apoptotic cells
and function as potential CD36 ligand (112,113,114). The Hazen group has
shown that some of these lipid oxidation products have aldehydes at the 
position (115,116). Through this research, a relationship between lipid
oxidation and immune recognition has evolved, suggesting that oxidized
lipids play important role in inflammation and that they are involved in the
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development of atherosclerosis. Some of the OxPLs are pro-atherogenic and
some are anti-atherogenic (117,118). Thus, the complexity of OxPL activity
requires additional investigation into the characterization of these lipid
aldehydes.
Previously, Jian et al. identified a novel carboxylate-containing aldehyde, 5,8dioxo-6(E)-octenoic acid (DOOE), that was formed from 5(S)-HPETE, a 5LOX-mediated AA oxidation product (36,119). One difference between 15LOX and 5-LOX is that 15-LOX can use esterified AA or lipoprotein as
substrate, while 5-LOX can only oxidize free arachidonic acid (120). Thus, it
was considered more worth studying the decomposition of 15-LOX-derived
15(S)-HPETE into reactive aldehydes. The resulting aldehyde could also
potentially exist in an esterified form and so would be present on the surface
of membrane where it could act as a signaling molecule.
The mechanism of HPETE decomposition to aldehydes is still not
completely clear, although several groups have proposed some potential
schemes (as shown in chapter 1). It is extremely challenging to capture the
reactive intermediates that are precursors of the resulting aldehydes due to
rapidity of potential radical reactions and the instability of any radical
intermediates. Thus, we studied the chirality of the final aldehyde product, 4hydroxy-nonenal (HPNE) at its C4 position, similar as the method used by
the Brash Group (see Chapter 3). The chirality of HPNE formed from different
precursors indicated that there were two distinct decomposition pathways

97

from 15-HPETE and 11(R)-HPETE. Furthermore, the made it possible to
determine the relative contributions of different HPETEs to HPNE levels.

Figure 4.1 Chemical structures of 15-HPETE, 11-HPETE, OUDE1 and 2,
and OUDE Girard T derivative
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Figure 4.2. Proposed mechanism for formation of OUDE from 15(S)HPETE and 11(R)-HPETE

4.3 EXPERIMENTAL PROCEDURES
4.3.1 Chemicals and Reagents.
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AA, HPNE and [2H3]-4-HNE were purchased from Cayman (Ann Harbor, MI).
Girard T reagent, hydroxylamine hydrochloride, L-glutathione, L-ascorbic acid,
and lipoxidase from Glycine max (soybean) were purchased from SigmaAldrich (St. Louis, MO). LC-MS grade water, tert-Butyl methyl ether,
methanol, isopropanol, acetonitrile and dichloromethane were obtained from
Fisher Scientific (Pittsburgh, PA). Gases were supplied by The Linde Group
(Munich, Germany).
4.3.2 MS conditions.
For oxime derivatives analysis, the Finnigan LTQ mass spectrometer (Thermo
Electron, San Jose, CA) was used in the positive ion mode with an ESI source.
The operating conditions were: spray voltage at 4 kV; capillary temperature
at 250°C; capillary voltage at 35 V; nitrogen as sheath (40 psi) and auxiliary
(20 arbitrary units) gas. CID was performed using helium as the collision gas
in the ion trap. The following SRM transition (m/z 188 → 154) was monitored
for HPNE-oxime (normalized CE, 25 %), and SRM transition (m/z 172 → 99)
was monitored for HNE-oxime (normalized CE, 25%).
For GSH adduct analysis, the triple stage quadrupole (TSQ Quantum) mass
spectrometer (Thermo Electron, San Jose, CA) equipped with an ESI source
was used. TSQ Quantum was operated in the positive ion mode with an ESI
source. The operating conditions were: spray voltage at 4 kV; capillary
temperature at 350°C; nitrogen as sheath (35 psi) and auxiliary (13 arbitrary
units) gas. CID was performed using argon as the collision gas at 1.5 mtorr
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in the Rf-only quadrupole.

The following SRM transition (m/z 464 → 308)

was monitored for HNE-GSH (CE, 14 eV).
For high resolution mass analysis, the Thermo LTQ Orbitrap XL hybrid FTMS
(Fourier Transform mass spectrometer) equipped with a Michrom nano ESI
source was used. It was operated in negative mode for free fatty acid
analysis, while in positive mode for Girard T derivatives analysis. The
operating conditions were: spray voltage at 1.75kV; capillary temperature at
250 ˚C; capillary voltage at 49 V; helium as collision gas. For full scan, the
resolution was set at 30 000. For MS/MS, the isolation width used was 2.5,
the resolution for the products analysis was 30 000, and the collision energy
was 35 %.
4.3.3 LC methods.
LC separations were conducted using a Waters Alliance 2690 HPLC system
(Waters Corp., Milford, MA, USA). A Chiralpak AD-RH column (150 × 4.6 mm
inner diameter, 5 µm; Daicel Chemical Industries, Ltd., Tokyo, Japan) was
used for reverse phase (isocratic method 1, flow-rate 0.5 ml/min) separation
of the HNE and HPNE oxime derivatives.

The mobile phase for isocratic

separations was methanol/water (85:15; v/v) containing 0.1 % formic acid.
OUDE was purified by preparative LC (Ultrasphere™ 250 × 10 mm, inner
diameter, 5 µm; Beckman) using Hitachi LC system by monitoring the UV
absorbance at 236 nm. The mobile phase for isocratic method 2 was
hexane/isopropanol (97:3; v/v) with 0.1 % acetic acid as the modifier.
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GSH-adducts were separated by reversed phase using gradient 1 on Waters
Alliance 2690 HPLC system.

The separation employed a Phenomenex

Synergi Hydro-RP column (150 × 4.6 mm inner diameters, 5 µm). Solvent A
was

0.1%

aqueous

formic

acid,

and

methanol/acetonitrile/formic acid (50:50:0.1; v/v).

solvent

B

was

Gradient 1 was as

follows: 2% B at 0 min, 12% B at 14 min, 30% B at 20 min, 42% B at 21
min, 65% B at 27 min, 80% B at 29 min, 90% B at 33 min, 90% B at 34 min,
2% B at 35 min. The flow rate was 0.4 ml/min.

The separation was

performed at ambient temperature using a linear gradient.
A Waters nanoAcquity UPLC system was coupled to the LTQ orbitrap XL. The
column used to separate free fatty acids or Girard T derivatives was a Waters
Acquity C18 (150 mm × 150 m inner diameter, 1.7 m). Solvent A was 0.1%
aqueous formic acid, and solvent B was acetonitrile with 0.1% formic acid.
The flow rate was 2 l/min, and the column temperature was 35 ˚C.
For fatty acid analysis, gradient 2 was as follows: 35% B at 0 to 6 min, 90%
B at 8 min, 98%B at 23 min to 26 min, and 35% B at 27 min till 37 min. For
Girard T derivatives, Gradient 3 was as follows: 10% B from 0 min to 6 min,
50% B at 8 min, 80% B at 23 min, 98% B from 24 min till 27 min and 10%
B from 28 min to 38 min.
4.3.4 NMR method.
NMR Spectra were determined at ambient temperature on a Bruker Avance
500 instrument. 1H experiments were carried out at 500 MHz. The samples
(0.5-0.8 mg) were dissolved into 300 ml CDCl3. The data processing was
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performed on the spectrometer. Chemical shifts are expressed in parts per
million (ppm) downfield from the residual solvent peak of 7.26 ppm for CDCl3
for 1H NMR. Splitting patterns are indicated as follows: br, broad; s, singlet;
d, doublet; t, triplet; q, quartet; dd, doublet of doublets; dt, doublet of
triplets.
4.3.5 GSH derivatization.
The lipid hydroperoxides decomposition reactions were performed in the
presence of 4 mM GSH, and then the aldehydes GSH conjugates were formed
during the incubation at 37 C for 30 min. Then the reaction mixtures were
loaded to SPE cartridges (HLB, Oasis, 30 mg) which were pre-conditioned by
adding 1 ml methanol and 1 ml water. After loading samples, the cartridges
were washed with 1ml water to remove excess GSH, and then 0.5 ml
methanol was added to elute the analytes. The elutent was directly analyzed
by LC-ESI/SRM/MS or concentrated under N2 flow.
4.3.6 Girard T derivatization.
Aldehydes in 200 l buffer (100 mM MOPS, 150 mM NaCl, pH7.2) were added
with 10 l acetic acid and 1 mg Girard T reagent. The reaction mixture was
kept at room temperature for 30 min and then transferred to SPE cartridge
(HLB, Oasis, 30mg) pre-conditioned with 1 ml methanol and 1 ml water. The
cartridge was then washed with 1 ml water, and then 0.5 ml methanol added
to elute analyte. The elutent was evaporated to dryness in N2 flow, and
dissolved in 100 µl of water/acetonitrile (95:5; v/v). The solution was then
transferred to Costar Spin-X nylon centrifuge
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filter (0.22

m), and

centrifuged at 10 000 x g for 5 min. Then the clear solution was analyzed by
nano UPLC-ESI/MS.
4.3.7 Preparation of OUDE.
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Figure 4.3 Synthesis of OUDE1 and OUDE2.
Methyl 11-(tetrahydro-2H-pyran-2-yloxy)undeca-5,8-diynoate (5). Methyl
hex-5-ynoate 4 (2.76 g, 21.85 mmol) was added to a mixture of K2CO3 (5.03
g, 36.40 mmol), CuI (4.51 g, 23.67 mmol) and NaI (5.46, 36.40 mmol). The
mixture was stirred for 30 min and 3 (139) was added. The reaction was
stirred for 16 hrs. Ether (200ml) was added and washed with saturated NH4Cl
solution, water and brine. The solvent was evaporated for chromatography
(10% EtOAc in Hexanes) to supply 5 (3.24 g, 61%). δH (500 MHz, CDCl3)
3.92-3.67(m, 5H), 3.35 (s, 3H), 2.53-2.38 (m, 8H), 2.24-2.22 (m, 4H),
1.83-1.81 (m, 4H).
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(5Z,8Z)-Methyl 11-(tetrahydro-2H-pyran-2-yloxy)undeca-5,8-dienoate (6).
NiOAc.4H2O (0.68 g, 2.73 mmol) was dissolved in MeOH (20 mL) and the
flask was flashed with H2 three times. NaBH4 (75 mg, 1.98 mmol) in NaOH (8
mL, 0.2 M) was added in one portion. After gas evolution had subsided, 0.8
mL of ethylenediamine was added and the mixture was stirred for 5 min. A
(1.60 g 5.48 mmol) in methanol (2 mL) was added and the hydrogenation
was continued for 4 hrs. The mixture was filtrated and the solvent was
evaporated. The residue was taken up with EtOAc and washed with water.
The organic layer was evaporated for flash chromatography (10% EtOAc in
Hexanes) to provide 6 (1.0 g, 62%). δH (500 MHz, CDCl3) 5.42-5.35(m, 4H),
4.59-4.58 (m, 1H), 3.87-3.83 (m, 1H), 3.75-3.70 (m, 1H), 3.65 (s, 3H),
3.50-3.47 (m, 1H), 3.42-3.37 (m, 1H), 2.79-2.77 (m, 2H), 2.36-2.29 (m,
4H), 2.10-2.07 (m, 2H), 1.82-1.69 (m, 8H).
(5Z,8Z)-Methyl 11-hydroxyundeca-5,8-dienoate (7). PTSA.H2O (1.83 g, 9.62
mmol) was added to a solution of 6 (0.95 g, 3.21 mmol) in methanol (20 mL)
and stirred overnight.

20 mL sat. NaHCO3 was added to the mixture and

methanol was evaporated.
washed

with

brine.

The

The mixture was then extracted with EtOAc and
organic

layer

was

evaporated

for

flash

chromatography (20% EtOAc in Hexanes) to provide 7 (558 mg, 82%). δH
(500 MHz, CDCl3) 5.50-5.46 (m, 1H), 5.40-5.33 (m, 3H), 3.64-3.61 (m, 5H),
2.79-2.77 (m, 2H), 2.33-2.29 (m, 4H), 2.09-2.04 (m, 3H), 1.69-1.66 (m,
2H).
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(5Z,8Z)-Methyl 11-oxoundeca-5,8-dienoate (8). Dess-Martin reagent (2.00 g,
4.71 mmol) was added to a solution of 7 in DCM (20 mL) and stirred for 2
hrs. Sat. NaHCO3 (20 mL) was added to the mixture and the mixture was
extracted

with

DCM.

The

organic

layer

was

evaporated

for

flash

chromatography (20% EtOAc in Hexanes) to supply 8 (490 mg, 99%). δH
(500 MHz, CDCl3) 9.66 (s, 1H), 5.65-5.49 (m, 4H), 3.66 (s, 3H), 2.33-2.319
(m, 5H), 2.16-2.09 (m, 1H), 1.69-1.66 (m, 4H).
(5Z,8Z)-Methyl

11,11-dimethoxyundeca-5,8-dienoate

(9).

Trimethylorthoformate (227 mg, 2.41 mmol) was added to a solution of 8
(50 mg, 0.238 mmol) and CeCl3.7H2O (92 mg, 0.25 mmol) in MeOH (10 mL)
and stirred for 2 hrs. 10 mL sat. NaHCO3 was added to the mixture and the
mixture was extracted with EtOAc. The organic layer was evaporated for
flash chromatography (10% EtOAc in Hexanes) to provide 9 (40 mg, 66%).
δH (500 MHz, CDCl3) 5.49-5.36 (m, 4H), 4.39-4.38 (m, 1H), 3.67 (s, 3H),
3.33 (s, 6H), 2.79 (bs, 1H), 2.41-2.30 (m, 4H), 2.17-2.05 (m, 1H), 1.701.67 (m, 4H).
(5Z,8Z)-11-Oxoundeca-5,8-dienoic acid (10) and (5Z,9E)-11-oxoundeca-5,9dienoic acid (11). 3N LiOH (2mL, 6 mmol) was added to a solution of 9 (40
mg, 0.156 mmol) in THF (5mL) and stirred for 2 hrs at 60 °C. The mixture
was extracted with EtOAc after acidification with 3N HCl. The organic layer
was evaporated for flash chromatography (EtOAc) to provide the crude acid
(30 mg, 79%).
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3N HCl (1 mL, 6 mmol) was added to the above crude acid in ACN (5 mL)
and stirred for 2 hrs at r.t. The mixture was extracted with EtOAc. The
organic layer was evaporated for HPLC (Beckman, Ultrasphere, 250x10 mm,
UV: 236 nm, Hexane/isopropanol/acetic acid = 97:3:0.1, 2.5 mL/min,
isocratic method 2).
4.3.8 Lipid hydroperoxides decomposition in the presence of Vit C or
iron.
15(S)-HPETE (5 µg) in 200 µl Chelex-treated 100 mM MOPS buffer (pH 7.2),
containing 150 mM NaCl was incubated with 1 mM Vit C at 37 °C for 24 hr.
Ethyl acetate (2×800 µl) was added to extract products. The organic layer
was evaporated and dissolved to 100 µl MeOH/H2O (4:6, v/v). The solution
was filtered by Costar nylon 0.22 m filter and 2 µl of each sample was
injected to UPLC-ESI-LTQ Orbitrap/MS (gradient 3). For GT derivatives, the
method was described previously in section 4.3.6.
4.3.9 Chirality character of HPNE-oxime derivative formed from
hydroperoxides.
HPETEs (300 µM) were incubated at 37 ºC with 2 mM Vit C in 200 µl Chelextreated MOPS buffer (100 mM, pH 7.2), containing 150 mM NaCl. After 1 h, 1
mg hydroxylamine hydrochloride was added to the reaction mixture and the
incubation was continued for 1 h before extraction with diethyl ether (2 X
600 µl). Ethyl layer was evaporated in N2. Samples were dissolved into 100
µl MeOH/water (85:15; v/v), and 20 µl was injected to LTQ-ESI/SRM/MS
(isocratic method1).
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4.3.10 Characterization of epoxide alcohol formed from 15(S)-HPETE.
To confirm the formation of epoxide alcohol from 15-HPETE, the reaction
mixture was first purified by MTBE and then the organic phase was
evaporated and re-dissolved into 200 l acetonitrile containing 0.1 N HCl.
Here acetonitrile instead of buffer was used to prevent water competing with
chloride ion to attach to the epoxide. The mixture was kept for 30 min at
room temperature, and then diluted 10 times before analyzed by nanoUPLCLTQ orbitrap-ESI/MS.

4.4 RESULTS
4.4.1 Preparation and confirmation of OUDE.
OUDE was chemically synthesized as described above. When the reaction
mixtures were purified using Hitachi a semi-preparative LC-UV system, two
peaks collected, which shared the same molecular weight, the same
retention

time

on

UPLC

C18

column

and

even

the

same

MS/MS

fragmentation when they were detected by the LTQ-Orbitrap (Figure 4.4)
Thus, they were named OUDE as OUDE1 and 2, depending on the elution
order from semi-preparative column. OUDE1 had a retention time of 13.4
min, while OUDE2 was eluted at 16.4 min.
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Figure 4.4. LC-orbitrap/MS/MS data of synthetic OUDE and its isomer.
The top channels are corresponding the retention of OUDE1 and 2 on C18
column, while the lower spectrum show the MS/MS fragmentation of OUDE1
and 2 at collision energy 35%.

NMR was performed for these two isomers (Figure 4.5). For OUDE1: δH (500
MHz, CDCl3) 9.68 (s, 1H), 5.69-5.40 (m, 4H), 2.80-2.78 (m, 2H), 2.44-2.32
(m, 2H), 2.15-2.02 (m, 2H), 1.73-1.61 (m, 4H). For OUDE2: δH (500 MHz,
CDCl3) 9.50 (d, J = 8.0 Hz, 1H, H-11), 6.85 (dt, J = 15.5, 8.0Hz, 1H, H-9),
6.15 (dd, J = 15.5, 8.0Hz, 1H, H-10), 5.43-5.37 (m, 2H), 2.79-2.73 (m, 2H),
2.42-2.24 (m, 4H), 1.73-1.64 (m, 4H). The insert in the OUDE2 NMR
spectrum is the enlarged chemical shift range from 5.5 to 7 ppm. The
doublet of triplets peak splitting pattern of H9 and the doublet of doublets
pattern of H10 indicate the C9-C10 double bond, and also indicate C10 is the
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one close to the terminal aldehyde. These patterns were not observed in
OUDE1, so OUDE2 is the C8-C9 double bond translocation of OUDE1.
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Figure 4.5. The NMR spectra of OUDE1 and OUDE2 at 500 MHZ.
4.4.2 Lipid hydroperoxides decomposition in the presence of Vit C or
iron.
15-HPETE and 11(R)-HPETE underwent decomposition in the presence of Vit
C or iron, and the decomposition products were analyzed by reverse phase
LC coupled with high resolution orbitrap MS in the negative mode (Figure
4.6). To increase the detection sensitivity, the aldehydes products were
converted to Girard T derivatives (Figure 4.7). [13C20]-11(R)-HPETE was
synthesized from [13C20]-AA by 11-LOX enzyme (a kind gift from Dr. Alan
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Brash, Vanderbilt University). The reaction conditions and purification
conditions were same as for unlabeled 11(R)-HPETE or 15(S)-HPETE. Figure
4.7(g) shows a mass spectrum of the [13C11]-OUDE GT derivative derived
from [13C20]-11(R)-HPETE decomposition, Figures 4.7(d) to 4.7(f) shows the
product ions from the MS/MS analysis of OUDE GT at collision energy of 35%,
while the lower mass spectrum shows the product ions from [13C11]-OUDE GT
at same collision energy. It is clear that the product ions observed in Figure
4.7(g) mass spectrum have an 11 Da mass shift when compared to the
product ions in Figures 4.7(d) to 4.7(f). This not only indicates that OUDE
contains eleven carbons, but also indicates that these ions arise from
cleavage of a Girard T moiety.
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Figure 4.6. LC-MS detection of OUDE from 15(S)-HPETE and 11(R)HPETE.
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Figure 4.7. LC-MS/MS of OUDE-GT derivative and [13C11]-OUDE-GT
derivative.

However, based on this evidence alone it remains unknown whether OUDE1
or OUDE2 is formed from HPETE decomposition, since these two isomers and
their GT derivatives have the same elemental compositions, similar retention
times, and also MS/MS fragments. Thus, OUDE was conjugated with
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hydroxylamine to make the oxime derivative (to increase MS response by
introducing a nitrogen atom) and then Chiralpak AD-RH column was applied
to separate these isomers. Both OUDE1 and OUDE2-oxime were split into
two peaks, which corresponded to syn- and anti-isomers, due to the newly
formed C=N double bond. Figure 5, clearly shows that OUDE1-oxime and
OUDE2-oxime are well separated on the AD-RH column. From this Figure, it
is also evident that 15(S)-HPETE-derived OUDE is a mixture of OUDE1 and
OUDE2 isomers.

Figure 4.8. Chiral LC-MS detection of OUDE-oxime derivative from
15(S)-HPETE and authentic OUDE. (a) shows OUDE-oxime from 15(S)HPETE decomposition, (b) shows authentic OUDE-oxime, while (c) shows
OUDE-oxime with double bond translocation.
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4.4.3 Chirality of HPNE-oxime derivatives formed from eicosanoids.
In order to determine

a potential decomposition mechanism, HPNEs

generated from HPETE decomposition were converted to oxime derivatives
and separated on AD-RH column. In Figure 4.9, it is evident that HPNE
derived from 15-HPETE retains the original chirality at C-15 position, while
HPNE from 11(R)-HPETE was a racemic 1 to 1 mixture. Thus, it is proposed
that the 15-hydroperoxy group in 15-HPETE does not participate in the
decomposition of HPETE to HPNE. In contrast, it appears that for 11(R)HPETE, a beta scission occurs at C-11 (Figure 4.1).
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Figure 4.9. The chiral characters of HPNE formed from HPETEs.
Figures a to d show the chromatography of HPNE hydroxylamine derivative
(HPNE-oxime) formed from 11(R)-HPETE, 15(S)-HPETE, 15(S)-HPETE methyl
ester and 15(R)-HPETE methyl ester, respectively. Figure (e) is the
chromatography of racemic HPNE-oxime standard. HPNE-oxime is separated
by reverse phase LC, and monitored by SRM transition m/z 188 to 154.

4.4.4 Characterization of epoxide alcohol formed from 15(S)-HPETE.
To confirm the hypothesis that an epoxide alcohol was a major intermediate,
the 15(S)-HPETE reaction mixture was incubated with 0.1 N HCl, and the
products were analyzed by LC-MS (Figure 4.10). The relative intensity ratio
of 371.1995 to its highest isotope peak 373.1965 is 3 to 1, which agrees with
the predicted ratio. This isotope distribution pattern confirms the presence of
Cl and indicates the original compound contained an epoxide group. Figure
4.10(d) shows the MS3 product ion spectrum from the MS2 product ion,
317.2121, which is an HCl elimination product. The ion at m/z 193.1235 was
generated through cleavage between C12 and C13, while the ion at m/z
235.1340 was formed by cleavage between C14 and C15, together with loss
of a water molecule (Figure 4.10 d).
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Figure 4.10. Hydrolysis of epoxide in the presence of 0.1 N HCl. Figure,
(a) is the reconstructed ion of 371.1995 with 3 ppm window. The product ion
spectrum of this peak is shown in (c), where 371.1995 indicates the mass
assignment was correct to the fourth decimal place.
The ion at m/z
37
373.1965 corresponded to the Cl isotopomer. The lower channel (d) shows
the MS3 product ions derived from the ion at m/z 371.1995.

4.5 DISCUSSION:
The novel aldehyde OUDE was identified as a product from the nonenzymatic decomposition of 15-HPETE and 11(R)-HPETE. Two OUDE isomers
were identified. OUDE2 contains an ,–unsaturated aldehyde and so can be
considered to be a carboxylate-containing analog of ONE. These two OUDE
isomers differ by the location of C9-C10 double bond, so they or their GT
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derivatives cannot be distinguished simply by LC-MS analysis. However, they
show different NMR spectra and different retention times on Chiral AD-RH
column. Although the driving force for the double bond translocation is
unknown, both isomers were observed in the decomposition of 15- and 11HPETE. This phenomenon also indicates the complexity of the products that
can arise from lipid oxidation. The bis-allylic hydrogen atoms that are present
in AA can be readily replaced by molecular oxygen while the number of
double bonds contributes to the formation of complex structural isomers.
15-HPETE is the primary product of 15-LOX, and numerous studies have
shown that 15-LOX is involved in oxidized LDL formation. This is based on
the evidence that there is co-localization of 15-LOX and oxidized LDL (122,
123). It is not completely clear how 15-LOX contributes to LDL oxidation.
There are several potential explanations. First, although 15-LOX is a cytosolic
enzyme, it might be excreted out of cells when cells are under injured
conditions. Once the LDL membrane is oxidized by 15-LOX, changing of
hydrophobicity would cause a re-alignment of the original membranes. The
oxidized moiety would flip up and be present on the membrane surface,
where it could be recognized by the CD36 receptor (113). Second, oxidized
LDL could be taken up by macrophage cells, and since LDL is rich in
unsaturated fatty acids, such as linoleic acid and AA, which could be
substrates for 15-LOX-mediated oxidation for further oxidation. There is
evidence showing 15-LOX is active in the presence of lipid drops (124). Third,
the lipids oxidized by 15-LOX might be released from cells and be recruited
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by LDL. It was reported that oxidized fatty acids could be incorporated into
membranes and play important biological roles (125,126, 127).
11-Oxo-ETE is rapidly excreted from LoVo cells (chapter 2), and so it is
possible that there are also an export transporters for other oxidized lipids.
Yoshimoto and colleagues suggested a potential mechanism, which involved
the exchanging of cholesteryl esters of LDL with cell membranes and the
relocation of 15-LOX to the LDL binding site (128). 11(R)-HPETE is the major
product from the LOX-like activity of COX. Since the substrate of COX has to
be free fatty acids, then it is less likely that COX will directly oxidize LDL.
However, COX will generate free OUDE1 and OUDE2, which could be secreted
and transported to other cells or LDL.
In summary, there is substantial evidence suggesting a relationship between
oxidized lipids and immune recognition. The studies described above have
shown that 15-LOX and COXs can contribute to the formation of oxidized
lipids with structural similarity to immunogenic lipids. This provides a
potential novel pathway by which lipids could be involved in immune
recognition.
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Chapter 5
Conclusion and future directions

5.1 Conclusions
COX-2 converts AA into PGG2, 11(R)-HPETE, 15(S)-HPETE and 15(R)-HPETE
(Chapter 3). Although there are intense studies showing that COX-2
contributes to cancer development by generating PGE2, which is proinflammatory and oncogenic, the studies described above have revealed that
the PGG2 and the HPETEs can decompose to shorter chain aldehydes HNE
and ONE, which could be involved in a myriad of biological processes
(Chapter 3). 11(R)-HPETE was found to generate a racemic mixture of
4(R,S)-HNE, while PGG2 and 15(S)-HPETE generated only 4(S)-HNE and
15(R)-HPETE generated only 4(R)-HNE. HNE and ONE can cause oxidative
stress by GSH depletion, or alternatively, they can modify proteins and DNA,
resulting in the dysregulation of protein function or causing DNA mutations.
4(S)-HNE was the major enantiomer identified in COX-2-expressiong LoVo
cells, suggesting that its major source was it’s the initially formed COXderived product of AA oxidation, PGG2. Earlier studies have shown that HNE
can be derived from HPNE, which also serves as the precursor to ONE. This
suggests that any COX-2-derived ONE also arose from PGG2 decomposition
rather than the HPETEs as had been previously suggested. No ONE dGuo
adduct (H-dGuo) was found in COX-2 expressing LoVo cells, suggesting that
DNA repair was more efficient than in rodent epithelial cells or that the ONE
was detoxified more rapidly. Therefore, additional human cell lines should be
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examined to determine whether H-dGuo can be detected. If human cells do
have advanced DNA repair system the excised DNA-adduct may be present
in urine, which would be a good biomarker for exposure to COX-2-mediated
DNA-adduct formation. 15-HPETE and 11(R)-HPETE also generate the
carboxylate-containing

aldehydes,

OUDE

1

and

2,

which

might

be

incorporated into membranes and function as signaling molecules, for
example, the ligand of CD36 receptor (Chapter 4). Thus, not only 15-LOX is
related to OxPLs formation, but also COX-2. There are many enzymes
involved in the conversion of COX-2-derived AA metabolites into other
eicosanoids. The ability of 15-PGDH to oxidize 11(R)-HETE into 11-oxo-ETE
was clearly demonstrated. The resulting 11-oxo-ETE I rapidly secreted from
cells presumably by the action of membrane transporters, or is further
transformed by GST/GSH or unknown reductases (Chapter 2). 11-Oxo-ETE
might play an important role in inhibiting endothelial cell proliferation.
Additional studies will be required in order to elucidate the anti-proliferative
effect of 11-oxo-ETE. Considering the structural similarity of 11-oxo-ETE to
other oxidized lipid products, it might either bind to PPARand activate PPAR
regulated gene transcription or bind the cysteine residue of the NF-B DNA
binding domain and inhibit NF-B activity. Such future mechanistic studies
would further our understanding of how the COX-2/15-PGDH pathway is
involved in the regulation of tumorogenesis. Clearly, the physiological levels
of these AA metabolites are controlled by multiple pathways, and the
changing of any of these pathways would cause a shift in the eicosanoid
levels, and initiate a series of biological consequences. The studies described
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above have provided additional insight into how such changes could impact
on pathophysiological processes.
LC-MS techniques were critical for the studies on AA metabolites, because of
the high sensitivity and specificity that could be obtained when compared
with other techniques, such as LC-UV or LC-NMR. Moreover, it was possible
to analyze a broad spectrum of metabolites because they did not have to
possess UV activity. Most of the metabolites could be analyzed by LC-MS,
chemical derivatization was used in some cases to increase the MS response.
Specific examples of derivatives that were used included PFB, GT, and
oximes (Chapters 2 and 3). Moreover, LC coupled with high resolution MS
further increased the detection specificity, since most high resolution MS
(HRMS) can give mass accuracy to the third or fourth decimal place (Chapter
4),

which

facilitated

the

determination

of

a

compounds

elemental

composition and structure elucidation. In addition, another advantage of LCMS is that it could analyze crude samples with minimal sample purification
procedures, although a de-salting process (SPE method) was required in
order to avoid complex adduct formation between the analyte and different
cations such as sodium, potassium or ammonium.

5.2 Future directions
Considering the complexity of AA metabolism, the major limit of current
methodology is that it focuses on limited numbers of metabolites within a
specific cell line. Therefore, it is difficult to conclude whether these targets
are the major metabolites and decide which ones are undergoing the most
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significant

changes

when

comparisons

are

made

between

different

treatments. The growth of metabolism software and metabolite databases,
together with HRMS, will make it possible to begin addressing these issues
(129, 130). Newly launched mass spectrometry platforms, such as LTQOrbitrap, TripleTOF 5600, and Q-exactive, all provide high resolution capacity,
which facilitate good mass accuracy (131, 132, 133). The data from different
cell treatments or from different population after analyzed by HRMS can be
loaded to a software package such as XCMS or SIEVE in order to determine
the most significant changes. Initially the software aligns the chromatograms
and then and after alignment of the LC chromatography, the software will
extract peaks based on retention time and m/z. It will then provide the
relative levels of different metabolites initially identified by comparing m/z
information to the existing database, such as Metlin, chemical spider, and
lipidmaps (134, 135, 136). However, the small molecule metabolite
databases are far from completion, and compared to proteomic databases, it
is more complex to assign specific structure. This is due to the enormous
diversity of structures that can be encountered with small molecule
metabolites (<1500 Da). Thus, more basic discovery research will be
required in order to make the databases more complete.
The analysis of small molecule metabolites based on HRMS is rarely enough
to provide accurate quantitation and complete specificity, since no single tool
is currently available is applicable to every experimental design. Besides LCMS, NMR is also crucial for unknown metabolite structure elucidation. The
characterization of OUDE isomers in chapter 4 is a good example. However,
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NMR does have a major limitation it lacks the sensitivity to analyze trace
amounts of metabolites.
Gene and protein expression changes will modulate metabolite levels, and in
complex feedback relationships, fine tuning of metabolites will also affect
genes and proteins through direct modifications or multiple-step signal
transductions. Mapping the interaction between metabolic genes, enzymes,
and small molecule metabolites is the ultimate goal of metabolism study. The
combination of genomics, proteomics, and metabolomics tools will help to
understand the multiple layers of regulatory mechanisms governing cellular
signaling, and will also help to uncover more disease related pathways or
targets (137, 138, 139). As described in chapter 1, aspirin is an important
drug, not only because of its anti-inflammatory effect, but also because its
potential anti-cancer benefit. It is well know that aspirin inhibit PG formation
through acetylation of COX-1 and COX-2. It is believed that there are other
possible pathways, other than inhibition of PGs, which are also regulated by
aspirin to inhibit cancer development (140-142). The acetylation of other
proteins or enzymes by aspirin might affect the formation of other
metabolites.. Ultra performance liquid chromatography (UPLC) coupled with
high resolution MS will facilitate the analysis of such metabolites in an
accurate yet efficient way, which will be highly complementary to the
proteomics analysis of acetylated proteins.
In addtion, considering the incredible complexity of biological system, the
variations of metabolite biosynthesis will also depend on the cell types or
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tissues, as well as the species being studies. Thus, simple comparison of two
samples in one dimension of biological complexity is less meaningful without
taking other biological variations into consideration. To draw a picture of
metabolites level in different tissues or species or human subjects will require
the teamwork from different research groups. A recently published integrated
colon cancer genomic study is a good example showing large variations from
different sample types and the teamwork enables the researchers get the
genomics information from different types of colon cancer (143). By systemic
study, it was possible to identify the most frequent gene mutations from
different tumors. This information can also provide important guidance for
the analysis of small molecule metabolites from colon cancer, as they
highlight certain pathways for further study. However, the factors causing
DNA mutations are not well-understood yet. Thus, our findings of new
bioactive aldehydes generated from COX-2 might contribute to DNA damage,
even though it has not been yet been possible to fully evaluate the
importance of COX-2-derived AA metabolism. Therefore, it might be worth
building a database for DNA adducts, so that different research groups could
develop screening methods for DNA-adduct detection from different types of
samples. In this way, it would be possible to connect the major DNA adducts
to sample types, which would in turn would provide a better understanding of
the relationship between the pathways causing DNA-adduct formation and
the resulting DNA mutations. This would ultimately provide better targets for
chemoprevention based on specific sample types.
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